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Trypanosoma brucei, the causative agent of the disease African sleeping sickness 
in humans and nagana in animals, is a scourge of sub-Saharan Africa. There is a 
desperate need for more efficacious therapies for the disease; here we describe research 
validating T. brucei hexokinase 1 (TbHK1) as a drug therapeutic target for T. brucei 
infection and the identification and characterization of novel inhibitors of the enzyme by 
both low throughput and high throughput means. Additionally this thesis introduces 
efforts at characterizing a second T. brucei hexokinase, focusing mostly on cell biology 
and the determination of localization. 
The small molecule quercetin (QCN) was tested and found to inhibit recombinant 
TbHK1 and spectroscopic study revealed that quercetin binds to TbHK1 proximal to the 
active site. Genetic experiments revealed that QCN may be cytotoxic to parasites as a 
result of TbHK inhibition. QCN localized to punctate bodies and the flagellum of T. 
brucei (consistent with the localization of TbHKs) and over expression of TbHK1 was 
partially protective. 
In order to identify additional TbHK1 inhibitors, high through-put screening 
(HTS) techniques were implemented. HTS of >220,000 compounds yielded 239 primary 
inhibitors of TbHK1. Of the 239 hits, 15 were confirmed in validation assays as TbHK1 
inhibitors; these compounds had a spectrum of activity against trypanosomes, suggesting 
possible therapeutic leads. 
In order to initiate characterization of the unknown function of TbHK2, 
localization studies of TbHK2 were performed. Immunofluorescence assays were 
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employed and TbHK2 was found to localize to the parasite’s flagellum, a novel finding 
that suggests that glycolysis in the parasite may not be limited to glycosomes, organelles 
related to peroxisomes that heretofore were considered the cellular compartments of 
glycolysis. Immunofluorescence signal was not exclusive to the flagellum but was 
observed in the cytosol and glycosomes. To understand the mode of localization, the 
TbHK sequences were aligned with known and predicted flagellum proteins and a 
conserved flagellum localization peptide signal was identified in the C-termini of TbHK1 
and TbHK2. The peptide signal (RAVLAK) was further explored as a flagellum targeting 
sequence using fusions to a reporter. These experiments, along with expression and 
localization of HA-tagged TbHK2 revealed that TbHK2 associates with the flagellum and 
basal body. This unusual localization suggested that TbHK2 may act as an environmental 
glucose sensor or perhaps in energy production for the active flagellum. 
The appendix is comprised of three chapters. The first appendix section is a 
published paper that focuses on AMP dependent protein kinase from T. brucei. I 
contributed microscopic expertise (and intellectual input) and am an author on this work. 
The second appendix section is a summary of research performed to characterize a library 
of lonidamine analogs against TbHK1 and trypanosomes. And lastly, the third appendix 
section is the developed assay for testing the viability of T. brucei cells and adaptation for 
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 Trypanosoma brucei is the causative agent of African sleeping sickness in humans 
and nagana in cattle. Both diseases are endemic to the sub-Saharan regions of Africa 
where the insect vector, the tsetse fly, is found. Approximately 500,000 people in sub-
Saharan Africa are infected per year with 50,000-70,000 deaths per year [Stich 2002]. 
The defining feature of the disease is the complete exhaustion experienced by the 
infected host [Dauvilliers, 2008]. Eventually, if untreated, the host will slip into a coma 
and die. There are two main progressions of the disease in which the parasite is either 
only localized to the host blood stream or the parasite has crossed the blood-brain barrier 
[Amin, 2008].  
 However, even with treatment the host may still die, as current drug therapies can 
be deadly in their own right [Enserink, 2007]. Most of the available approved drugs are 
arsenic derivatives that are noxious with side effects including blindness [Barrett, 2003], 
encephalopathy and death [Pepin 1991]. Approximately 10% of patients die when taking 
the drug melarsoprol to treat human African trypanosomiasis (HAT) [Docampo 2003]. 
Drugs are required in part because a vaccine is not available for treating T. brucei 
infections. Future vaccine development is unlikely because this ancient eukaryotic cell 
can evade the host immune system as a population through a process known as antigenic 
variation [Hartley, 2008]. In this process the parasite population presents a single surface 
molecule that the host will recognize and produce antibodies against. However, within 
 
the population, a small percentage changes the single surface protein and evades the 
antibody-mediated immune response. This causes a constant flux in parasitemia in which 
the host kills a majority of the parasites but a few survive to multiply and elicit another 
immune response when the parasite number reaches a threshold.  
 A vaccine would be possible if the number of surface molecules was finite. 
Unfortunately, the gene responsible for the surface molecule, variant surface glycoprotein 
(VSG) has multiple copies of multiple alleles that can recombine through homologous 
recombination [Hartley, 2008; Hutchinson, 2007]. Control of the single expression of one 
allele is based on the location of the VSG allele. There are 20 telomeric expression sites 
for VSG alleles. Each allele can be exchanged through homologous recombination but 
only one expression site is active [Dreesen, 2007]. Therefore, a useful vaccine would 
have to contain every probable combination of VSGs that could be produced. This is not 
likely to be obtainable because there are over 1000 alleles contained on 
microchromosomes in the genome [Taylor, 2006].  
  The effect of African sleeping sickness on human health is a problem for the sub-
Saharan regions of Africa but the effect on the economy is also important. The cattle 
industry suffers to the point where large herds cannot be sustained. In fact, European 
breeds of cattle are devastated by nagana. For this reason the sub-Saharan region of 
Africa has what are known as green deserts [Enserink, 2007]. In the green deserts ~4.5 
billion dollars are lost each year as a result of the unused land [Enserink, 2007]. Not only 
would this money be beneficial to struggling economies in this region but it would also 
bring food to the starving. Therefore, combating T. brucei will not only alleviate a human 
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health hazard but also increase the wealth of the region and potentially combat world 
hunger. 
 
Trypanosoma brucei: a model organism 
 T. brucei is a flagellated unicellular parasitic eukaryote. T. brucei also has some 
characteristics that make it a model organism for genetic studies. One such characteristic 
is the fact that most T. brucei genes do not contain introns – an example of an exception 
is poly(A) polymerase which has been shown to contain a single intron of 653 
nucleotides [Mair, 2000]. The lack of introns makes it easier to predict open reading 
frames, clone full length genes, and recombinantly express genes in prokaryotic cells. 
Also, the parasite undergoes the biological phenomenon known as RNA interference 
[Balaña-Fouce, 2007]. With RNA interfence, gene expression can be reduced without 
producing a knockout. Homologous recombination is another characteristic that makes T. 
brucei amenable genetic system, allowing knock ins and knock outs to assess gene 
function [Barnes, 2007]. These facts make T. brucei very attractive as a genetic model 
organism.  
 The life cycle of the parasite is composed of two major stages: the insect procyclic 
form and the bloodstream form. From both environments T. brucei can be cultured and 
studied. Curiously, the two stages have different metabolisms. In the insect form the 
primary metabolism used by the parasite is through the TCA cycle and the metabolism of 
proline [van Hellemond, 2005]. Within the tsetse fly amino acids are at high 
concentrations and thus readily available [Schneider, 2008]. However, the environment is 
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different within the bloodstream of mammalian hosts. The bloodstream is rich with 
glucose when compared to the fly and upon differentiation from insect to bloodstream 
form T. brucei shifts its metabolism to rely exclusively on glycolysis [Besteiro, 2005].  
 
Glycolysis as a drug target 
 Glycolysis is an exploitable pathway for therapy development. This metabolic shift 
is the weakness that can be exploited to kill the parasite. The BSF parasite cannot survive 
disruption of glycolysis [Verlinde, 2001]. When the parasites differentiate to the 
bloodstream form they change not only their metabolic pathway to that of glycolysis but 
also lose most functionality of the singular mitochondrion through the repressed 
expression of mitochondrial targeted proteins [Williams, 2008]. Therefore, without a 
completely functional mitochondrion, inhibition of the glycolytic pathway is toxic. 
 Glycolysis in the African trypanosome occurs in the specialized organelles known 
as glycosomes [Opperdoes, 2006]. This is distinct from most organisms in which 
glycolysis is cytosolic. Targeting of proteins to the glycosome is mediated by two peptide 
sequences known as peroxisomal targeting sequence 1 (PTS 1) [Gould, 1989] and 
peroxisomal targeting sequence 2 (PTS 2) [Blattner, 1995]. PTS1 sequences are found on 
the C-terminus of proteins while PTS2 sequences are found on the N-terminus of 
proteins. Both PTS sequences mediate the incorporation of glycosomal proteins. 
 However, all glycolytic and metabolic enzymes are not exclusive to the glycosome. 
The metabolic enzyme adenylate kinase has been shown to be found in the flagellum of 
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T. brucei [Pullen 2004]. In Leishmania, a HK has been found to moonlight as a heme-
binding protein in the flagellar pocket [Krishnamurthy 2005].  
 Flagellum localization in T. brucei is also accomplished by peptide targeting 
sequences [Ersfeld 2000]. One such targeting sequence is found near the C-terminus of 
proteins and was described for the flagellum protein paraflagellar rod A (PFRA) [Bastin 
1999]. For TbHKs to localize to the flagellum a peptide sequence would be expected. 
Mitochondrial HKs have also been described and these are physically associated with the 
mitochondrial membrane [Crane 1952]. In Chlamydomonas and mammalian sperm, 
glycolytic enzymes have been found in the flagellum [Mitchell 2005; Lardy 1941]. 
 
TbHKs 
 Two hexokinases named TbHK1 and TbHK2 are expressed in BSF and PF parasites 
[Colasante, 2006]. Arranged in tandem on chromosome 10, the two polypeptides are 98% 
identical, with 7 of 10 differences in the C-terminus region of the protein. These changes 
are influential in ATP binding [Chambers, 2008 BBRC]. TbHKs have previously been 
localized to the glycosome where T. brucei undergoes glycolysis [Opperdoes, 2006]. 
 Biochemical studies have revealed that authentic and recombinant TbHKs 
multimerize in to hexamers [Opperdoes, 2006; Morris 2006]. Notably recombinant 
TbHK2 (rTbHK2) is not active by itself but in complex with rTbHK1 the enzyme is 
active [Chambers, 2008 JBC].  
 Genetic evidence supports the targeting of TbHK1 in therapeutic development. 
TbHK1 has been shown to be essential through RNAi of the 3’ UTR of TbHK1 in 
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bloodstream form parasites [Morris, 2002]. RNAi of TbHK1 and TbHK2 led to cell death 
due to a disruption of glycolytic flux [Albert, 2005].  
 Biochemical validation of TbHKs as therapeutic targets has also been considered. 
Inhibitors of TbHK1 can be tested easily in vitro by using a simple hexokinase assay. 
Using such an assay TbHKs have been shown to be sensitive to fatty acids [Chambers, 
2008 JBC]. Structurally based inhibitors of TbHK have been used in the past but are 
trypanocidal at high concentrations [Trinquier 1995][Willson 2002].  
 In an attempt to uncover more efficacious trypanocidal compounds that use TbHK 
as a target, known HK inhibitors were tested against TbHK1 and trypanosomes. From 
these inhibitors of hexokinases, two were investigated, lonidamine and quercetin. 
 
Lonidamine 
 Lonidamine (LND, 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid) has been 
shown to inhibit hexokinases bound to the mitochondrion of mammalian cells [Paggi, 
1988]. Thus, LND is described as an inhibitor of aerobic glycolysis. Over the years, LND 
mediated hexokinase inhibition has been used for two major applications: cancer 
therapeutics [Silvestrini, 1991] and male contraception [Silvestrini, 1984]. 
 
LND as an anticancer therapeutic agent 
 Cancerous cells and other proliferative cells have a high demand for energy. 
Therefore, if metabolic pathways are inhibited the cancerous cells are predicted to die. 
Because LND inhibits hexokinase it inhibits glycolysis and is used as a therapeutic 
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treatment for cancer. Currently, LND is used in Europe against cancers such as lung and 
breast cancers [Pasquale, 2005]. However, LND is mostly used in the treatment of benign 
prostatic hyperplasia (BPH) [Pasquale, 2005]. BPH is a disease that is becoming more 
frequent due to increased male life expectancy. The prostate is an ideal target for LND 
because the area depends solely on glycolysis for energy [Guzman, 1994]. This is due to 
a zinc-mediated enzyme block in the citric acid cycle of prostate gland cells because the 
prostate secretes abnormally high levels of citrate and zinc [Costello, 2000]. Therefore, 
replication of the cells of the prostate is inhibited by LND. In fact patients with BPH have 
seen a reduction in prostate volume when taking LND [Pasquale, 2005]. 
 
LND as a male contraception agent 
 LND works as a male contraception drug because it inhibits the growth of fertile 
spermatigotes, preventing maturation of spermastigotes [Yan Cheng, 2002]. Because new 
spermatigotes are produced constantly in males this contraception drug is reversible when 
LND treatment is stopped [Maranghi, 2005]. However, LND has not yet been approved 
for use as a male contraceptive in humans. 
 
LND as an inhibitor of TbHK1 
 Recently, LND has been found to inhibit rTBHK1 in vitro [Chambers, 2008 LND]. 
The inhibitory concentration (IC50) for LND is 850 μM. But when the drug is tested 
against bloodstream form parasites it has a lethal dose (LD50) of 50 μM [Chambers, 2008 
LND]. The increase may be due to the fact that the inhibition of TbHK1 does not have to 
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be complete to be toxic to the parasite or off target effects. Another factor could be the 
relative concentration of LND within the glycosome. LND may be concentrated within 
the glycosome while in the culture it is at a lower concentration or LND may be affecting 




 Quercetin, 3,5,7,3’,4’ pentahydroxyflavone (QCN), is a bioflavonoid isolated from 
plants such as apples, onions, and capers [Cerhauser, 2008, Slimestad, 2007, Sharaf, 
2000]. QCN has been shown to exhibit antioxidant properties [Bischoff 2008] as well as 
play a role in the signaling between plants and microbes for nodulation [Novak 2002]. 
Over the years, QCN has been used as a probe because of the fluorescent nature of the 
molecule [Guharay 2001]. The fluorescent property is also useful for determining protein 
binding because QCN fluoresces differently when bound to protein such as bovine serum 
albumin [Sengupta 2002]. But the key feature of QCN is that it inhibits enzymes such as 
tyrosine protein kinase, a phosphorylase kinase [Srivastava 1985], a phosphatidyl 3-
kinase [Matter 1992], and a DNA topoisomerase [Boege 1996]. The proposed mode of 
inhibition has been suggested to be the formation of a hydrogen-bonded complex with 
ATP [Granot 2002]. This complex may mimic the transition state of ATP and the tyrosyl 





Quercetin fluorescence experiments 
 As previously mentioned, QCN is used in protein binding experiments. Proteins like 
human serum albumin (HSA) have been used in these experiments. When QCN binds to 
HSA, the nature of QCN emission changes such that it exhibits a second major emission 
wavelength [Sengupta 2002]. The phenomenon known as fluorescence resonance energy 
transfer (FRET) can be used to indicate the proximal location of QCN binding to the 
protein when exciting tryptophan at 280 nm. If FRET occurs between the protein and 
QCN then the relative location of QCN binding is near a tryptophan residue. For protein 
molecules with a singular tryptophan, the location of QCN binding can then be assumed 
to be within 5 nm of the tryptophan due to the maximum distance limitation of FRET 
[Lakowicz 1983]. 
 
Quercetin as a drug therapy for HAT 
 QCN has been shown to inhibit the growth of cancer cell lines such as Ehrlich 
ascites tumors and NK/Ly ascites tumor cells [Suolinna 1975, Molnar 1981]. The target 
of QCN within the cells is unknown. It has been proposed that the target may be Src 
protein kinase (pp60v-src) [Graziani 1983] or HKs [Graziani 1977]. 
 QCN not only affects cancer cells. QCN appears to affect any rapidly dividing cell, 
even BSF parasites [Mamani-Matsuda 2004]. QCN is toxic and induces apoptosis at a 
relatively low level with an LD50 of 10 µM QCN [Mamani-Matsuda 2004]. While the 
connection between QCN and apoptosis is not resolved, apoptosis is linked in 
mammalian cells with mitochondrial associated hexokinase activity [Gottlob 2001]. In 
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 The creation and discovery of novel chemical compounds and drugs has been an 
on-going goal of pharmaceutical companies and chemical labs. Now there are a 
tremendous number of compounds that have been produced. In order to take advantage of 
these created compounds, libraries have been constructed with these compounds and 
drugs in order to accommodate their use in screens. 
 One approach to discovering therapies for HAT is to use chemical libraries in high-
throughput screens (HTS). HTS can be used to assess the viability of T. brucei cells 
[Mackey 2006]. The drawback of using a HTS to identify inhibitors of cell growth is that 
the target of the drug will remain unknown and identifying the target may be extremely 
difficult. Additionally, target-based screens allow for refinement of lists in silico based on 
the structures and activities of the target. 
 In order to circumvent such problems, target based HTS has been used. In such an 
approach the HTS is put to test against an in vitro assay. Then hits from the enzyme assay 
are tested against cells. This approach allows the investigators to assume at least one of 
the targets of the inhibitor within the cell. Enzyme assays such as UDP-Glc 4’-epimerase 
and trypanothione reductase have been used with success to identify inhibitors of 
trypanosome viability [Ubaniak 2006; Martyn 2007]. 
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 The TbHK1 assay is a coupled reaction with the production of glucose-6-phosphate 
linked to the conversion of glucose-6-phosphate to 6-phosphogluconolactone in the 
presence of the enzyme glucose-6-phosphate dehydrogenase [Parry 1966]. The reduction 
of NADP+ to NADPH from the last step is observed spectrophotometrically and can be 
formatted to fit a 384 well plate design. In order for the TbHK1 assay to be used in a HTS 
the assay must have an appropriate Z-factor score. The Z-factor score is a mathematically 
calculated value that approximates the efficiency of a HTS. Basically, the Z-factor score 
is a measurement of the maximum and minimum values of the assay. A value above 0.5 




 The literature review is a supplemental for the following three chapters. The next 
two chapters comprise research using TbHK1 as a drug target. The first is on the research 
performed using QCN as a TbHK1 inhibitor, trypanocidal compound and a molecular 
probe for TbHK binding. The next chapter is the high throughput screen in which 
additional compounds were found to inhibit TbHK1 and kill T. brucei.  
 The last chapter is focused on the localization of TbHK2. Localization studies have 
revealed that TbHK2 is found in the flagellum and cell bodies including glycosomes and 
basal bodies. The flagellum localization appears to be mediated through a similar 
flagellum targeting sequence as that found and described in this chapter. The function of 
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Hexokinases from the African trypanosome, Trypanosoma brucei, are attractive targets 
for the development of anti-parasitic drugs, in part because the parasite utilizes glycolysis 
exclusively for energy production during the mammalian infection.  Here, we have found 
that both recombinant Trypanosoma brucei hexokinase 1 (TbHK1, IC50 = 86 µM) and 
authentic TbHK activity from cell lysates were inhibited by the trypanocidal bioflavanoid 
quercetin (QCN).  Spectroscopic analysis of QCN binding to TbHK1, taking advantage 
of the intrinsically fluorescent single tryptophan (Trp177) in TbHK1 revealed that QCN 
quenches Trp177 emission.  ATP similarly quenched Trp177 emission, while glucose had 
no impact on fluorescence.  QCN interaction with TbHK1 led to the production of a 
distinct fluorescence emission at 460 nm.  This fluorescence, characteristic of flavanols 
bound to proteins, was inhibited by glucose but unaffected by ATP.  These spectroscopic 
studies suggested that ATP and QCN bind TbHK1 at a similar location near Trp177 
while glucose binding altered the TbHK1 conformation sufficiently to prevent dual 
fluorescence from the flavanol.   
QCN was toxic to bloodstream and procyclic form parasites (LD50s of 7.5 µM and 
35 µM, respectively) possibly as a result of inhibition of the essential TbHKs.  
Supporting this idea, RNAi-mediated silencing of TbHK expression in procyclic form 
parasites expedited QCN-induced death, while over-expressing TbHK protected parasites 
from the compound.  Additionally, QCN fluorescence suggested a cellular distribution 
similar to that of TbHKs.  In summary, these observations support the suggestion that 









Trypanosoma brucei is the causative agent of human African trypanosomiasis 
(HAT) and nagana, a wasting disease, in livestock.  The World Health Organization 
classifies T. brucei as a re-emerging/uncontrollable human pathogen, partly due to a lack 
of a vaccine and suitable treatments for the disease.  Current therapeutics for HAT may 
have serious side effects, including blindness and death (1). 
 T. brucei relies exclusively on glycolysis for energy generation in the mammalian 
bloodstream.  Hexokinases (HK1) catalyze the first step in glycolysis facilitating the 
transfer of the γ-phosphoryl group of ATP to the C6 of glucose.  The parasite expresses 
two HKs, TbHK1 and TbHK2, with proteomic studies revealing that both are found in 
the mammalian bloodstream (BSF) and insect (PF) forms of the parasites (2). 
 TbHK1 and TbHK2 are 98% identical at the amino acid level (3).  RNA 
interference (RNAi) has been used to demonstrate that both enzymes are essential to the 
BSF parasites, as silencing of either TbHK1 or TbHK2 results in the loss of HK activity 
and cell death (4,5).  In addition to this genetic evidence validating TbHKs as potential 
therapeutic targets, we have found that chemicals that inhibit HKs from other systems 
also inhibit TbHKs and are toxic to the trypanosome.  For example, the anticancer drug 
lonidamine (LND) inhibits recombinant TbHK1 and HKs from parasite lysate and is 
toxic to both BSF and PF parasites (5).  LND trypanocidal activity likely results in part 
from inhibition of TbHKs. Parasites were partially protected from LND-induced cell 
death by ectopic over-expression of TbHK1. 
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 Quercetin (3,5,7,3’,4’ pentahydroxyflavone, QCN) is an abundant naturally 
occurring flavanol found in plants such as apples, onions, and capers.  QCN and related 
flavanols are of interest as potential anti-cancer therapies, because they inhibit the growth 
of several types of cancer cell lines (6,7).  Potential in vivo QCN targets include a number 
of enzymes that are inhibited in vitro, ranging from the Src protein kinase (pp60v-src) to 
HKs (8,9).   
Biophysically, QCN has several unusual fluorescence properties, including 
intramolecular excited-state proton transfer and dual fluorescence behavior that have 
been exploited in the use of flavanols as environmental probes (10).  Additionally, QCN 
binding to bovine serum albumin has been studied using these spectral properties (11).  
These efforts suggest that QCN could be a useful tool in the study of target enzyme 
mechanisms if the target enzyme has a single tryptophan residue proximal to a site of 
interest.    
 Here, we have characterized the impact of QCN on recombinant TbHK1 and 
transgenic parasites.  Our work builds on the observation that QCN is toxic to 
trypanosomes (12), revealing that TbHK1 may be a molecular target of the flavanoid.  
We have found that over-expression of TbHK1 provides protection from QCN, while 
RNAi depletion of TbHKs expedites parasite death.  Additional spectroscopic 
investigations taking advantage of the intrinsic fluorescence of QCN suggest that QCN 






Materials and Methods 
Reagents 
Quercetin dihydrate (QCN, 3,3’,4’,5,7-pentahydroxyflavone) was purchased from 
Spectrum Chemical Manufacturing Corporation (Gardena, CA).  
 
Trypanosome cell culture and transfection 
BSF parasites (cell line 90-13, a 427 strain) were grown in HMI-9 supplemented 
with 10% fetal bovine serum and 10% Serum Plus (Sigma-Aldrich, St. Louis, MO). PF 
parasites (29-13, a 427 strain) were grown in SDM-79. The T7 RNA polymerase and the 
tetracycline repressor constructs were maintained by the addition of 2.5 µg/ml G418 and 
5 µg/ml hygromycin to the medium.  PF parasites were transfected and selected as 
described (13).  RNAi specific for TbHK1 was performed by targeting the unique 3’UTR 
of the transcript.  Briefly, RNAi of TbHK1 was achieved using pZJM harboring a 341 bp 
fragment previously identified as a 3' untranslated region sequence (14).  Parasite growth 
was monitored on a Becton-Dickinson FACScan flow cytometer. 
 For studies exploring the impact of over-expression of TbHK1 in PF cells, 
parental cells (PF 29-13) were transformed with linearized pLew111(2T7)GFPβ (15) 
harboring the TbHK1 gene in the multicloning site.  This vector fuses the green 
fluorescent protein (GFP) to the carboxyl termini of expressed proteins.  After selection 
for stable transformants, TbHK1 expression was induced by addition of tetracycline (1 






Assays of recombinant and lysate-derived HK 
Recombinant TbHK1 was expressed and purified as described previously (3).  
Parasite lysates were prepared by hypotonic lysis of 1 x 107 cells in the presence of 1 mM 
PMSF, 20 mg/ml leupeptin, and 100 mg/ml TLCK.  The mixture was added to lysis 
buffer (for a final concentration of 0.1 M triethanolamine (TEA) pH 7.4 and 0.1% Triton 
X-100) and lysates used in HK assays. 
HK assays were performed in triplicate using a coupled reaction.  Briefly, assays 
used glucose 6-phosphate dehydrogenase (1 unit/assay, EMD Biosciences, Inc, San 
Diego, CA) as a coupling enzyme to reduce NADP+ to NADPH during the oxidation of 
glucose-6-P to 6-phosphogluconic acid (3), a reaction that can be monitored 
spectrophotometrically.  Final conditions were 0.1M TEA, pH 7.9 containing 1.0 mM 
ATP, 33 mM MgCl2, 20 mM glucose, and 0.75 mM NAD+. Assays were performed in 
96-well microtiter plate format in a GENios spectrophotometer (Phenix Research 
Products, Hayward, CA).   
 
Tryptophan Quenching Assay of TbHK1 
Glucose, ATP, and QCN were added at varying concentrations individually and in 
combination to a solution (3 ml) of 0.1M TEA, pH 7.4.  A scanning spectrofluorometer 
(Photon Technology International, Birmingham, NJ) was used to monitor emission from 
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300-550 nm after excitation of the lone Trp on TbHK1 (W177) at 280 nm.  After 
acquiring background emission, TbHK1 (~1 µg) was added to the cuvette, mixed by 
inversion, and an emission scan performed.   Using the PTI software, the area under the 
emission curves from 370-380 nm was integrated. Values were converted into the percent 
of Trp emission lost and plotted versus concentration of substrate/inhibitor using 
KaliedaGraph software version 4.03.  Sigmoidal curves were fit to the plots and IC50 
values were determined for the substrate/inhibitor by setting y equal to 50 and solving for 
x using the sigmoidal equation. 
 
Spectroscopic Binding Assay of TbHKs and QCN 
To explore QCN binding to TbHK1 or TbHK2, QCN (100 μM), ATP (1 mM) 
and/or glucose (20 mM), and TbHK1 or TbHK2 (16 nM) were mixed in a 100 mM TEA 
(pH 7.4) solution.  The sample was excited at 280 nm and excitation monitored from 300-
550 nm.  Spectra were gathered from 3 independent samples, with representative data 
presented. 
 
QCN Localization in T. brucei by Fluorescence Microscopy 
For microscopic examination of QCN localization, T. brucei were grown to 1 x 
106/ml (BSF 90-13) or 1 x 107/ml (PF 29-13), harvested (800 x g, 10 min) and washed 
twice in modified PBS (5 mM KCl, 8 mM NaCl, 1 mM MgSO4, 20 mM Na2HPO4, 2 mM 
NaH2PO4, 20 mM glucose).  QCN (100 µM) was then added to cells in the modified 
PBS.  After incubation (15 min, at growth conditions), cells were pelleted, washed twice, 
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and applied to slides after the addition of VectaShield mounting medium with DAPI 
(Vector Laboratories, Inc., Burlingame, CA).  Images were captured by epifluorescence 
microscopy (Axiovert 200M, Carl Zeiss MicroImaging, Inc., Thornwood, NY). 
For glycosome labeling, the aldolase peroxisomal targeting sequence (PTS2) (16) 
was introduced into a yellow fluorescent protein (YFP) modified pXS (17) expression 
vector to yield an N-terminal fusion with YFP.  Briefly, two primers FPTS2 
(5’AGCTTATGAGTAAGCGTGTGGAGGTGCTTCTTACACAGCTTG 3’) and RPTS2 
(5’CTAGCAAGCTGTGTAAGAAGCACCTCCACACGCTTACT CATA 3’) were 
annealed and the resulting product cloned into pXS.  PF parasites were then stably 
transfected with 10 µg of the pXSAldoPTSYFP construct and selected by supplementing 
the growth media with 15µg/mL blasticidin.  Live cells were visualized after 
resuspension in mounting medium (with DAPI) diluted 1:1 in PBS.   Alternatively, fixed 
PF cells were stained with a rabbit anti-T. brucei glycosomal antibody (2841D, (18)), 
raised primarily against the glycosomal proteins pyruvate phosphate dikinase, aldolase, 
and glyceraldehyde phosphate dehydrogenase (18) (the kind gift of Dr. Marilyn Parsons 
(Seattle Biomedical Research Institute, Seattle WA)).  Primary antibodies were detected 







QCN inhibits TbHK1, interacting with the enzyme near the active site - QCN has been 
shown to inhibit HK in cancer cells (9), suggesting that it might similarly inhibit 
rTbHK1.  Incubation of TbHK1 with QCN inhibits the enzyme (IC50 = 86 µM) (Fig. 1).  
Of note, QCN has does not cause dissociation of TbHK hexamers (a previously 
characterized mechanism for regulation of activity (19)) indicating that the inhibition that 
we observed are not related to dissociation of the hexamer (data not shown). 
To determine if endogenous HK activity from parasite lysates was also sensitive 
to QCN inhibition, cell lysates from either BSF or PF parasites were incubated with QCN 
and then assayed for HK activity.  QCN inhibited both BSF and PF HK activity similarly 
(with IC50s = 24 µM and 30 µM, respectively) (Not shown). 
TbHK1 inhibition coincides with changes in Trp fluorescence.  TbHK1 harbors a 
single Trp (residue 177) that is modeled to lie on the face of the enzyme near the hinge 
region (Fig. 2A) (3).  When this residue is excited with an excitation wavelength (λex) of 
280 nm, TbHK1 yields an emission band with a λem at ~370 nm (Fig. 2B, inset).  QCN is 
intrinsically fluorescent with a maximum emission wavelength of 550 nm. When excited 
at 280 nm, it yields little fluorescence at 370 nm.  Addition of increasing amounts of 
QCN to TbHK1, however, quenched the Tryp177 emission (Fig. 2B, inset), yielding an 
IC50 for quenching of ~ 35 µM (Fig. 2B).   
 Addition of glucose had minimal impact on Trp177 emission at 370 nm (not 
shown).  However, ATP quenched the Trp177 emission nearly completely at 5 mM and 
~20% at 0.05 mM (Fig. 2C).  Addition of glucose and ATP did not alter quenching, 




QCN excitation and emission as a result of intramolecullar energy transfer - Incubation 
of QCN with TbHK1 alters the emission profile acquired with a λex of 280 nm.   First, 
inclusion of TbHK1 in the analysis causes an alteration in fluorescence emission intensity 
at 540 nm (Fig. 3A), suggesting interacting with TbHK1 improves the fluorescent 
qualities of QCN.  Second, the mixture of QCN and TbHK1 yields a second λem at ~ 460 
nm.   This peak is characteristic of QCN bound to protein and results from typical dual 
fluorescence behavior common to flavanoids (11). 
 Glucose and ATP have different impact on the 460 nm peak observed when QCN 
and TbHK1 are spectrally analyzed.  Addition of glucose inhibits the generation of the 
460 nm peak but does not alter the 540 nm emission peak; this observation is true 
whether glucose is added before or after QCN (Fig. 3B).  ATP, on the other hand, does 
not impact the λem at 460 nm but instead reduces QCN emission at 540 nm, suggesting 
that ATP binding enhance the QCN-TbHK1 interaction (Fig. 3C).  Last, inclusion of both 
glucose and ATP leads to a loss of both the λem at 540 nm and 460 nm (Fig. 3D). Note 
that the spectra of glucose and ATP are equivalent to the background signal, while 
inclusion of either glucose or ATP with QCN had yielded traces indistinguishable from 
QCN alone (data not shown).   
While differing from TbHK1 by a total of 10 residues (out of 471), rTbHK2 does 
not interact with QCN to yield emission at 460 nm in the presence or absence of the two 
co-substrates glucose and ATP (Fig. 4). This finding indicates either a lack of QCN 
binding or a difference in binding that leads to a failure to coordinate QCN for productive 
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dual fluorescence.   (ATP and QCN, however, quench the 540 nm emission, as seen 
above.)   
 
QCN is toxic to T. brucei - Previous research has demonstrated that QCN is toxic to T. b. 
gambiense (LD50 = 10 µM) (12). To determine if the 427 T. b. brucei lab strain was 
susceptible to QCN, BSF 90-13 parasites were incubated for 24 hr in the presence of 
compound and growth monitored by cell counting.  QCN was found to be toxic to BSF 
parasites, with an LD50 = 7.5 µM (Fig. 5A).   QCN is also toxic to T. b. brucei PF 29-13 
trypanosomes, with an LD50 of 35 µM, nearly 5-fold higher than the LD50 for BSF 
parasites (Not shown). 
 
Exploring potential in vivo targets of QCN  - Glycolysis is essential to both BSF and PF 
parasites grown in standard culture medium.  Unlike BSF parasites (which rely 
exclusively on glycolysis for energy), genetic manipulation of glycolytic enzymes can be 
tolerated in PF parasites if the trypanosomes are first provided an opportunity to down-
regulate hexose metabolism.  Manipulations that are inducible, including over-expression 
and RNAi-based silencing of glycolytic enzymes, are examples that can be tolerated 
(3,14).   
 If QCN is toxic as a result of its inhibition of glycolysis, increased cellular HK 
polypeptide could temper the toxicity of the compound.  Cells over-expressing TbHK1 
from the inducible ectopic expression vector pLew111(2T7) were incubated with 50 µM 
QCN and cell growth monitored.  After 24 hrs, QCN-treated control parasites growth was 
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repressed 58%.  Cells over-expressing TbHK1, which displayed cellular HK activity 2.1 
greater than control cells (data not shown), were more resistant to QCN with growth 
reduced only 10% (Fig. 5B).  
The incomplete penetrance of RNAi (and the slowly developing phenotypes 
associated with the silencing) can allow manipulation of glycolytic enzyme abundance 
without cell toxicity in PF parasites (14).  Therefore, we have explored the sensitivity of 
the RNAi of TbHK1 using pZJM(TbHK1), which targets the distinct 3’UTR of TbHK1 
(14).  RNAi was induced for 24 hours before cells were passed into medium containing 
QCN and cell growth compared to parental PF 29-13 parasites after an additional 24 
hours.  Silencing TbHK1 led to enhanced sensitivity to QCN, with cells induced to 
silence TbHK1 reduced in number to 17% of the corresponding untreated cell lines (Fig. 
5B). 
Glycosomal localization of QCN in BSF parasites - QCN is taken up by T. brucei through 
an unknown mechanism.  To explore cellular localization of QCN, parasites were 
incubated with the compound and the inherent fluorescence of QCN scored by 
microscopy (Fig. 6).  Both PF and BSF parasites yielded punctate patterns of staining 
similar to that seen with either fluorescence localized by PTS2 to glycosomes in live 
parasites (Fig. 6) or using an antibody to label glycosomes in fixed parasites (3).   (The 
broad emission spectra of QCN limited immunofluorescence experiments, though similar 






BSF T. brucei generate energy exclusively by glycolysis, suggesting that inhibitors of 
enzymes in the pathway could be therapeutic lead compounds.  The trypanosome 
glycolytic enzymes, TbHK1 and TbHK2, are potential drug targets.  These proteins, 
which are 30-33% identical to those from yeast, plants, and mammals, have a number of 
unique biochemical features (in addition to amino acid composition) that suggest that 
identification of trypanosome-specific HK inhibitors may be possible.  These differences 
include multimerization of the enzyme into hexamers, localization of the protein to the 
glycosome, and sensitivity of the TbHKs to fatty acids (3,19,20).   
Genetic studies using RNAi have shown that both TbHKs are essential to the 
parasite (4,5), and chemical inhibitors of the enzyme have demonstrated anti-parasitic 
activity in vitro (5,21).  In an effort to identify and characterize new TbHK1 inhibitors, 
we have scanned the literature for HK inhibitors from different systems.  These efforts 
have yielded a number of small molecules, including QCN. 
 Here, we report that QCN, a previously recognized anti-trypanosomal flavanoid 
(12), inhibits recombinant TbHK1.  Many of the other enzymes that have been reported 
to be sensitive to QCN including a tyrosine protein kinase, a phosphorylase kinase (22), a 
phosphatidyl 3-kinase (23), and a DNA topoisomerase (24) share the feature of binding 
nucleotides or nucleotide triphosphates.  It has been suggested that QCN inhibits Tyr 
kinases (like pp60v-src) by forming a hydrogen-bonded complex with ATP, which would 
mimic the transition state of ATP and the tyrosyl residue of the enzyme (25).  A similar 
mechanism is unlikely in TbHK1, as QCN alone can quench Trp177 fluorescence and 
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QCN interacts with TbHK1 to yield a λem at 460 nm in the absence of ATP (Figs. 2 and 
3).   
We have reported previously that ATP binding is influenced by the unusual C-
termini of TbHK1 and TbHK2, which lies proximal to the hinge domain and Trp177 (Fig. 
2A) (26).  The majority of the differences between TbHK1 and TbHK2 (7 of the 10 total 
residue differences) are found in the terminal 18 amino acids of the polypeptide, and 
these differences yield catalytic differences between the proteins (3).  Two different 
TbHK1 variants harboring difference in the C-termini (I458V, V468A) had altered 
affinity for ATP, suggesting that the tail influences ATP binding (26).  Here, TbHK1 
QCN binding yields a 460 nm emission peak, while TbHK2 does not, suggesting again 
that the C-termini of the proteins influences small molecule binding.  The surprising 
difference in QCN binding between the two proteins suggests that TbHK1 is an in vivo 
target while TbHK2 may not be; an idea supported by our observation that the TbHK2 
knockout parasites share nearly identical LD50s for QCN with the parental PF 29-13 
parasites (data not shown).  
We have recently completed a screen of a library of 1280 pharmaceutically active 
compounds for small molecules that alter TbHK1 activity.  In this screen, we identified 
both inhibitors (that reduced activity > 50% at 10 µM) and activators (increased activity 
> 150% at 10 µM) of TbHK1 (data not shown).  Notably, we recovered one inhibitor, 
myricetin, which differs structurally from QCN by a single hydroxyl group.  One 
activator, taxifolin (dihydroquercetin), is also structurally similar to QCN, suggesting that 
the interaction can also positively influence enzyme activity. 
 32
 
QCN has been shown to trigger T. brucei death through apoptosis (12).  In 
mammalian cells, mitochondrial associated HK activity is required to prevent apoptosis 
(27) and increased HK activity prevents oxidant-induced apoptosis (28).  Our observation 
that QCN inhibits TbHK1 suggests that the apoptosis may result from a mechanism that 
measures HK activity, similar to that found in mammalian cells.  The TbHKs are unusual 
in a number of ways, including the finding that they oligomerize into hexamers (19) and 
localize to the peroxisome-like glycosome (20).  These characters suggest novel 
mechanisms connecting TbHK to cell signaling, which remain to be resolved. 
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Figure 1.  QCN inhibits TbHK1. (A) Increasing concentrations of QCN were incubated 
with TbHK1 (150 ng) for 1 hour at room temperature, and then assayed for HK activity 
as described in the Materials and Methods.  All assays were performed in triplicate. 
 
Figure 2.  QCN bound to rTbHK1 alters Trp177 fluorescence. (A) TbHK1 was modeled 
to S.cerevisiae hexokinase PII.  The active site, D214, and Trp177 are indicated, along 
with residues that are involved in ATP binding in the C-terminal tail.  For clarity, the 
lower lobe of the protein has been isolated and rotated to position the C-terminal tail 
perpendicular to the page.  (B) Trp177 emission is inhibited by QCN.  TbHK1 (1 µg) was 
incubated with QCN (100 μM) in a 100 mM TEA (pH 7.4) solution and, following 
excitation at 280 nm, emission monitored from 340-550 nm.  To assess the percentage of 
Trp emission lost, the region between 370-380 nm (inset) was calculated and the % 
reduction in response to QCN determined.  (C) ATP and QCN are additive in Trp177 
quenching.  Spectra were acquired from samples containing different amounts of ATP as 
described in 2B, and percentage of Trp emission lost calculated. 
 
Figure 3.  TbHK1 and QCN interact to yield an emission peak at 460 nm.   (A) Emission 
spectra from 400-550 nm of TbHK1, QCN, and TbHK1 incubated with QCN (A).  
Spectra were also collected from TbHK1 incubated with substrates, including glucose 




Figure 4.  TbHK2 and QCN do not interact to yield the 460 nm emission peak.  QCN 
alone or rTbHK2 incubated with QCN have similar emission spectra from 400-450 nm 
(A), while inclusion of ATP (B) quenches Trp177 emission.   
 
Figure 5.  (A) BSF trypanosomes grown in triplicate in HMI-9 medium were incubated 
for 24 hr with increasing amounts of QCN and densities determined by counting as 
described.  (B.) RNAi of TbHK1 enhances QCN toxicity, while over-expression of 
TbHK1 tempers it.   Parental PF trypanosomes (29-13) or parasites transformed with 
pLEW111(2T7):TbHK1 or pZJM:TbHK1 were  induced with tetracycline (1 µg/ml) for 
24 hours to either express or silence TbHK1, QCN (50 µM) added, and cell viability 
scored after an additional 24 hour incubation.     
 
Figure 6. Localization of QCN by microscopy in BSF and PF parasites.  BSF and PF 
parasites incubated with QCN (100 µM, 10 min and 1 hr for BSF and PF, respectively) 
were stained with DAPI and imaged.  Glycosome localization in live PF cells was 
visualized by eYFP emission.  Fluorescence of the QCN is captured here using a 488 nm 





























A TARGET-BASED HIGH THROUGHPUT SCREEN YIELDS TRYPANOSOMA 









The parasitic protozoan Trypanosoma brucei utilizes glycolysis exclusively for energy 
production during infection of the mammalian host.  The first step in this metabolic 
pathway is mediated by hexokinase (TbHK), an enzyme essential to the parasite that 
transfers the γ-phosphoryl of ATP to a hexose.  Here we describe the identification of 
novel small molecule inhibitors of TbHK1, which were then assessed for their impact on 
parasite viability.  These compounds were identified using a TbHK1 high throughput 
screen (HTS) assay format that couples the production of glucose-6-phosphate to a 
change in absorbance at OD340 through the activity of a reporter enzyme, glucose-6-
phosphate dehydrogenase.  Our HTS assay conditions were optimized and then validated 
using a pilot screen of a library of 1280 pharmaceutically active compounds.  This screen 
yielded 12 compounds that inhibited TbHK1 >50% at 10 µM and the resulting average Z-
factor of 0.69 ± 0.02 indicated that the in vitro assay was sufficiently robust for an HTS 
campaign.  Our interrogation of 220,233 unique compounds yielded 239 compounds as 
primary actives (>50% inhibition at 10 µM) for a 0.1% hit rate.  The average Z-factor for 
the screen was 0.80 ± 0.14 and subsequent IC50 value determinations confirmed TbHK1 
inhibitory activity for 10 small molecules.  Cluster analysis indicated that five 
compounds were structurally related while the remaining 5 compounds were classified as 
singletons.  Of these, three inhibited parasite growth with EC50 values < 50 nM with 
EC50s values for mammalian cell lines of >12.5 µM, suggesting promising target cell 
specificity.  These compounds represent novel leads for future therapeutic development 




African sleeping sickness conjures images of the past - of disease-induced fatal slumber 
striking down men, women, and children while the malady decimates villages of colonial 
Africa.  Unfortunately, people living in many countries of sub-Saharan Africa today 
know that African sleeping sickness is not a disease of history but rather is a much-
neglected disease of the present, particularly in areas that suffer the additional burdens of 
war, famine, and other infectious agents.  The causative agents of sleeping sickness (or 
human African trypanosomiasis, HAT) are subspecies of the African trypanosome 
Trypanosoma brucei.  Approximately 500,000 people in sub-Saharan Africa are infected 
annually with the parasite leading to 50,000-70,000 deaths per year (Stich et al., 2002).  
Few therapeutics are available and of the drugs currently used in the treatment of HAT 
most have serious adverse side effects, including encephalopathy and death (Pepin et al., 
1991).  Thus, there is a desperate need for new HAT therapeutics.  
 Bloodstream form (BSF1) T. brucei parasites generate energy exclusively 
through glycolysis and T. brucei hexokinase 1 (TbHK1), the first enzyme in glycolysis, 
has previously been validated as a target for therapeutic development.  In these 
experiments, BSF parasites were shown to be sensitive to RNA interference (RNAi)-
based silencing of TbHKs (Albert et al., 2005; Chambers et al., 2008), with cell toxicity 
observed after 3-5 days of RNAi exposure.  Further, known inhibitors of HKs from other 
systems have been demonstrated to inhibit TbHK1 and to be toxic to the parasite 
(Opperdoes et al., 2006).  However, while some mammalian HK inhibitors can inhibit 
TbHK1, TbHK1 is distinct enough from mammalian HKs to suggest that it can be 
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specifically targeted.  For example, TbHK1 shares only 30-33% sequence identity with 
the mammalian HKs, while differing in a number of ways including the fact that the 
trypanosome enzymes are found as hexamers (Misset et al. 1984).  Moreover, the unusual 
spectrum of known inhibitors of the trypanosome enzymes, including fatty acids and 
other small molecules (like pyrophosphate, (Chambers et al., 2008), support the idea that 
this essential parasite protein is sufficiently distinct from any mammalian counterpart to 
make an ideal target for therapeutic development.  Indeed, targeting TbHK using 
structurally based inhibitors has yielded trypanocidal compounds, albeit at high 
concentrations (Trinquier et al., 1995; Willson et al., 2002).   
Here we describe our target-based approach to identify and confirm specific 
inhibitors of the essential parasite enzyme, TbHK1.  Most of the potent TbHK1 inhibitors 
are toxic to culture grown BSF T. brucei while not exhibiting toxicity towards 
mammalian cells, suggesting that they may be useful lead compounds in the development 
of new therapies for African trypanosomiasis.   
 
Results 
Validation of optimized HTS assay conditions using the LOPAC set 
 The TbHK1 coupled assay was optimized and validated for HTS by screening the 
library of pharmaceutically active compound set (LOPAC).  Compounds were assayed in 
duplicate at a single concentration (10 µM) and reproducibility between the duplicate 
screens is represented in Fig. 1A (R2= 0.96).  Average Z-factors were 0.69 ± 0.02 for the 
two LOPAC assays demonstrating the robustness of the developed assay format (Zhang 
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et al., 1999).  Eighteen compounds inhibited TbHK1 enzymatic activity ≥ 40% at 10 µM 
including myricetin (48.9 ± 0.7%), a structural analog of quercetin, which we previously 
identified as a TbHK1 small molecule inhibitor (Lyda and Morris, unpublished 
observation) (Fig. 1B).  These data confirmed that our automated HTS assay conditions 
were robust and could be used to identify compounds that inhibited TbHK1 activity. 
 
Interrogation of 220,233 compounds for TbHK1 small molecule inhibitors. 
 We next screened 220,223 compounds at a single concentration (10 µM) for small 
molecule inhibitors of TbHK1.  The HTS assay performed robustly with average Z-
factors of 0.80 ± 0.1 and 239 compounds were identified as primary actives for an overall 
hit rate of 0.1%.  The 239 active compounds were cherry-picked and the initial inhibitory 
activity confirmed in the primary TbHK1 assay.  Additionally, the compounds were 
tested against the reporter enzyme, glucose-6-phosphate dehydrogenase, to determine if 
they interfered with the assay format.  After initial 20 point IC50 value determinations 
using cherrypicked compounds, 13 small molecules with IC50 values < 50 µM were 
obtained from commercial sources.  The activity of the resupplied compounds was 
empirically determined to control for possible TbHK1 inhibitory effects associated with 
compound library degradation.  Ten small molecules confirmed with TbHK1 IC50 values 
< 50 µM while 3 compounds failed to inhibit TbHK1.  Leadscope analysis of the 10 
confirmed TbHK1 inhibitors classified 5 compounds into a cluster of structurally related 
compounds (cluster 1) while the remaining 5 compounds were classified as singletons 
(Tables 1 and 2).  Ebselen (SID 856002) was the most potent compound in cluster 1 with 
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an IC50=0.05 ± 0.03 µM.  For the majority of the compounds IC50 values either improved 
or remained similar to cherry-picked compounds with the exceptions of SID 17386310 
and 14728414 (Table 2). 
Experiments aimed at exploring specificity of hits for TbHK1 included data 
mining of the PubChem Bioassay database to determine the frequency with which a 
compound has been found to be active in other assays.  In general, the cluster 1 
compounds have been active in other assays more frequently than the singletons, with 
SID 17387000 the most frequently active (identified in 14.1% of the 226 assays in which 
it was tested).  Singletons, on the other hand, were less frequently active.  For example, 
SID 14728414 was active in 2 of 210 assays (1%) (Table 2). 
Additional experiments to assess the in vitro specificity included testing the 
compounds against human glucokinases (hGlk).  This enzyme is similar in size, shares 
34% identity with TbHK1, and, like TbHK1, is not inhibited by its product glucose-6-
phosphate.  The activity against hGlck was varied, with the cluster 1 compounds yielding 
a spectrum of potency, from very low inhibition at 10 µM (for example, SID 17387000, 
with 6.7% inhibition, Table 1) to near complete inhibition by SID 856002 (ebselen, 
97.8% inhibition).  Singletons also demonstrated a spectrum of activity against hGlck, 
with SID 22401406 and 14728414 having minimal impact on the enzyme while 
16952891 and 17386310 were more potent inhibitors (Table 2). 
 
TbHK1 inhibitors are toxic to BSF parasites 
 49
 
TbHK1 has previously been shown to be an essential gene for BSF T. brucei (REFS), 
suggesting that inhibitors of the enzyme may be promising lead compounds for 
therapeutic development.  To initially explore this possibility, cultured BSF parasites 
were grown in the presence of 10 µM compound (dissolved in 1% DMSO, f.c.) and cell 
density monitored after 48 hr (Table 3).  The DMSO carrier had minimal impact on cell 
growth, with a ~20% reduction at the highest concentration used (1% f.c.) compared to 
untreated cells after 48 hr.  The 10 resupplied compounds were tested in this assay, with 
EC50s determined for those that inhibited cell growth >50% at 10 µM (Table 3). 
Compounds in cluster 1 included two of the most potent anti-trypanosomal compounds, 
SID 17387000 and 24785302.  Singletons were also toxic, with SID 17386310 being one 
of the most potent compounds tested to date.  Four molecules, including a member of 
cluster 1 (SID 3716597) and three singletons (SID 22401406, 24797131, 14728414) 
inhibited TbHK1 but were minimally toxic to BSF.    
With the exception of 856002 (ebselen), the resupplied compounds that were anti-
parasitic exhibited EC50 values that were 10-1000 fold lower than the IC50 values, 
suggesting possible off-target effects.  This discrepancy could alternatively result from 
the finding that TbHK1 is localized in a small peroxisome-like organelle, the glycosome, 
which may effectively concentrate the inhibitors.  Additionally, BSF parasites are 
sensitive to genetic manipulation that leads to decreased but not ablated TbHK1 
expression.  This suggests that modest inhibition of cellular TbHK1 activity could be 




Specificity of TbHK1 inhibitor toxicity 
To explore the likelihood of off-target effects, we first assessed the toxicity of the TbHK1 
inhibitors against PF parasites.  Unlike BSF parasites, PF parasites can utilize both amino 
acids and glucose for energy generation.  This dynamic metabolism suggests that the PF 
parasites may be less sensitive to TbHK1 inhibitors.  Indeed, at 10 µM most of the 
resupplied compounds had only a modest impact on PF parasite growth, inhibiting 
growth between 0-51% when compared to control cell lines.   
 Tests of target specificity also included assaying the HTS hits against other 
parasites.  Compounds toxic to T. brucei were assayed against a related kinetoplastid 
parasite, Leishmania major.  L. major promastigotes were typically less sensitive to the 
resupplied compounds (with EC50 values >12.5 µM), with the exception of ebselen, 
17387000, 17386310, and 24785302.  These compounds had EC50 values against L. 
major between 1-5 µM in exponentially growing parasites (Table 3).  Moreover, our 
identified TbHK1 inhibitors have minimal impact on human cells with EC50 values >12.5 
µM for all tested cell lines, suggesting at least 400-fold greater toxicity toward parasites 
for the most potent T. brucei cytotoxic compounds (data not shown).  
 
In silico analysis of ADME characteristics of the TbHK1 inhibitors 
 Experimental assessment of the ADME-Tox and physicochemical profile of an 
entire hit set from an HTS campaign represents a considerable challenge considering that 
we will end-up with several hundred to several thousand compounds. To rationally break 
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down these large numbers we performed an in silico assessment of ADME/Tox 
properties.  
 
Further characterization of two structurally related compounds 
Ebselen, 2-phenyl-1,2-benzisoselenazol-3(2H)-one, was the most potent resupplied 
TbHK1 inhibitor.  Resupply of the structurally related inhibitor 17387000 (2-phenyl-1,2-
benzisothiazol-3(2H)-one) yielded different IC50 values (0.05 ± 0.03 and 2.0 ± 0.5, for 
ebselen and 17387000, respectively).  In secondary assays, the two compounds behaved 
differently.  Ebselen was less potent against parasite lysate-derived TbHK activity than 
against the recombinant protein, with an IC50 of 10 µM, suggesting that the compound 
may be metabolized by cellular components.  Compound 17387000 was nearly as potent 
against lysate activity as against the recombinant protein, with an IC50 value against 
lysate enzyme of 8.6 µM.   
Additional differences include the activity of the compounds in screens against 
hGlck and parasite cells.   Ebselen was a potent inhibitor of hGlck (97.8% inhibition at 10 
µmM), while 17387000 had relatively little activity (6.7% inhibition) against the kinase 
(Table 1).  Additionally, ebselen was ~100-fold less active against BSF parasites (Table 
3), suggesting that the subtle differences between the two compounds yielded remarkable 
changes in their pharmacological behavior.  
Analysis of the nature of inhibition revealed subtle difference between the two 
molecules.  Ebselen inhibition was competitive with respect to ATP, while non-
competitive with respect to glucose.  This observation suggests that the inhibitor allows 
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glucose to bind but competes with ATP, leading to the formation of ternary E-I-glucose 
complexes (Willson et al., 1999).  Unlike ebselen, 17387000 was competitive with 
respect to both ATP and glucose, with Ki values of 0.62 µM and 1.2 µM, respectively. 
 
Discussion 
There are currently four drugs approved for treatment of HAT.  Suramin and 
pentamidine, developed in 1921 and 1941, respectively, are not effective against disease 
caused by T. b. rhodesiense.  Melarsoprol, which was introduced in 1949, leads to fatal 
complications in 10% of patients receiving the drug (Docampo et al., 2003).  The most 
recently developed drug, eflornithine, is efficacious against only T. b. gambiense, but is 
curative for both the early blood-borne infection and the late stage of disease that occurs 
when the parasite crosses the blood-brain barrier; delivery of eflornithine is difficult, as 
the compound must be administered intravenously four times a day for 14 days 
(delivering ~360g/patient).   
 A number of screens of chemical libraries have been undertaken to identify 
therapeutic leads against the African trypanosome.  These include a phenotypic screen 
that interrogated a library of FDA-approved drugs for anti-trypanosomal activity 
(Mackey et al., 2006), as well as screens developed to identify inhibitors of essential 
parasite enzymes.  A screen for UDP-Glc 4’-epimerase inhibitors using a small natural 
products library  (Urbaniak et al., 2006) and a screen of a commercial 134,500 compound 
library for trypanothione reductase inhibitors (Martyn et al., 2007) are two examples of 
target-based screens used to identify lead compounds for therapeutic development.   
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In the last few years, TbHK inhibitors have been explored as potential anti-
parasitic compounds.  Previous efforts to identify TbHK inhibitors include the 
development of compounds based on models of the TbHK structure (predicted from 
homology studies of the yeast structure), and exploring the activity of HK inhibitors from 
other systems (Opperdoes et al., 2006).  Here we have used a HTS of 220,223 
compounds to identify new inhibitors of the parasite enzyme.   
In our screens, we have identified several novel inhibitors of TbHK1.  One 
compound, ebselen, was the most potent inhibitor from the LOPAC validation screen and 
was the second most potent enzyme inhibitor identified in the HTS.  Ebselen is a lipid-
soluble seleno-organic compound that has been employed in clinical trials to assess its 
value in prevention of ischemic damage in brain hemorrhage and stroke (Saito et al., 
1998; Yamaguchi et al., 1998).  Ebselen inhibits lipid peroxidation through a glutathione 
peroxidase-like action (Muller et al., 1984), but may act through other mechanisms as 
well.  Notably, a single oral dose (100mg/kg) of ebselen yields serum values of 4-5 mM 
(Salom et al., 2004) and brain levels of the drug reach 21% of plasma levels (Imai et al., 
2001), suggesting that the compound (or its derivatives) may be useful for both early and 
late stage sleeping sickness therapy development.   
Ebselen likely has polypharmacological effects on BSF parasites, as the 
compound is known to inhibit a number of enzymes in addition to TbHK1, including the 
trypanosome UDP-Glc 4’-epimerase (Urbaniak et al., 2006).  The notable discrepancy 
between the IC50s and EC50s of the TbHK1 inhibitors identified here are also possibly the 
result of off-target inhibition.  Alternatively, differences between the two values could 
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result from the concentration of the compound within the parasite (perhaps in the 
glycosome) or metabolism of the inhibitor to a more potent form.   
An ideal therapeutic drug for African sleeping sickness would target only the 
parasite and work at concentrations low enough to limit the severity of side effects.  In 
the search for potential drug targets, we have focused on the trypanosome TbHK1, a 
protein that the parasite requires to make energy and have identified compounds that may 
serve as leads in for the development of therapeutics in the continuing fight against the 
African trypanosome.   
 
Materials and Methods 
Chemicals and Reagents.  Clear 384-well microtiter plates were purchased from Greiner 
(Monroe, NC) and used for all experiments.  Glucose-6-phosphate dehydrogenase, β-
nicotinamide adenine dinucleotide (NAD+), adenosine triphosphate (ATP), lipoic acid 
(Pubchem SID 11532893) and glucose were purchased from Sigma (St. Louis, MO).  
Phosphoenol pyruvate (PEP), ebselen (PubChem SID 856002) and glucosamine were 
obtained through VWR (West Chester, PA) and dimethyl sulfoxide (DMSO) was 
purchased from Fisher (Pittsburgh, PA).  The following PubChem SID compounds were 
obtained from commercial vendors: 3715577, 3716597, 24830882, 17386310, and 
16952891 (Enamine/Kiev, Ukraine); 24797131 and 14746394 (Chembridge/San Diego, 
CA); 14728414 and 17387000 (Specs/Delft, The Netherlands); 24785302, 24790923, and 
24814083 (University of Kansas Specialty Chemistry Center/Lawrence, KS); 17507245 
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(Asinex/Moscow, Russia) and 22401406 (Dr. K.H. Lee/University of North Carolina, 
Chapel hill, NC). 
 
Compound Libraries.  The library of pharmacologically active compounds (LOPAC) 
(1,280 compounds) was purchased from Sigma-Aldrich.  The Pittsburgh Molecular 
Libraries Screening Center (PMLSC) provided the 220,233 compound library screened 
for T. brucei hexokinase 1 small molecule inhibitor, which was made available as part of 
the NIH Molecular Libraries.  Cherry-picked compounds from the PMLSC library were 
supplied by BiofocusDPI (San Francisco, CA). 
 
Purification of Recombinant TbHK1.  For purification of recombinant TbHK1 
(rTbHK1), a previously described protocol (Morris et al., 2006) was modified to increase 
yield.  Briefly, a starter culture of E. coli M15(pREP) harboring  pQE30 (Qiagen, 
Valencia, CA) with TbHK1 cloned in frame of a 6-His tagging sequence was grown in 
ECPM1 {Wigelsworth, 2004 #1772} and then inoculated into a 5 L a bioreactor (Biostat 
B, B. Braun Biotech International, Allentown, PA) and grown at 37oC.  At OD600 
between 3-5, the culture was induced with IPTG (0.8 mM), grown without supplement O2 
(37oC, 16 hr), and cells collected by centrifugation (5000 x g, 20 min, 4oC).  The pellet 
was resuspended in lysis buffer (50 mM NaPO4, pH 8.1, 5 mM glucose, 150 mM NaCl, 
and 0.1% Tween) and lysed by using a cell disruptor (Constant Cell Disruption Systems, 
Sanford, NC).  The resulting supernatant was applied (5 ml/min) to a 50 ml ProBind 
column (Invitrogen, Eugene, OR) on a FPLC (GE Lifesciences, Piscataway, NJ) and 
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protein eluted by step gradient (5 to 250 mM imidazole) in lysis buffer.   Fractions were 
screened using HK activity assays and Western blotting and those containing rTbHK1 
were pooled, concentrated, and applied to a HiTrap SP HP column (GE Lifesciences, 
Piscataway, NJ).  Following elution, fractions harboring rTbHK1 were analyzed and 
determined to be ~95% pure based on coomassie stained SDS polyacrylamide gels.  
 
Automated primary TbHK1 HTS and glucose-6-phosphate dehydrogenase coupled 
assays.  TbHK1 assays were an adaptation of a coupled enzyme HK assay to a 384-well 
format (Morris et al., 2006; Parry and Walker, 1966).  Briefly, test and control 
compounds (30µM in 15µL volume) were added to a 384 well black, opaque microtiter 
plate using a Velocity 11 V-prep (Santa Clara, CA) for a final test compound 
concentration of 10 µM.   Negative (vehicle) controls contained 1% DMSO, positive 
controls contained 133 mM glucosamine and IC50 controls contained 1.3 mM 
glucosamine (final well concentrations).   A mixture containing glucose (1.5 mM), ATP 
(1.05 mM), MgCl2 (4.5 mM), NAD+ (9 mM), and G6PDH (0.018 mUnits/µL) in a 15 µL 
volume was then added to each well of the assay plate using a Perkin Elmer FlexDrop 
(Waltham, MA) followed by addition of rTbHK1 (1.5 ng/µl in 15µL volume).    The 45 
µL reaction mixture was incubated at RT for 2 hours and then quenched with 5 µL EDTA 
(500 mM).  The resulting signal, which remains stable for up to 5 hr after addition of stop 




 To account for possible inhibition of the reporter enzyme in the primary coupled 
reaction, putative inhibitors were screened to assess their activity against a G6PDH 
coupled assay.  Briefly, test and controls compounds were added to the wells of a 384 
well assay plates as described above. Negative (vehicle) controls contained 1% DMSO, 
positive controls contained 100 mM PEP and IC50 controls contained 8.6 mM PEP (final 
well concentrations).  A mixture containing glucose-6-phosphate (0.6 mM) and NAD+ (9 
mM) in a volume of 15 µL was then added to each assay plate well.  The reaction was 
initiated by addition of 15 µL G6PDH (0.018 mUnits/µL) and change in absorbance at 
OD340 was monitored as above.   
Additional specificity assays were performed using human HK 4 (human 
glucokinase, hGlk, GenBank accession no. BC001890) that was expressed from a cloned 
cDNA (OPEN Biosystems, Huntsville, AL) in pQE30.  After sequencing, the plasmid 
was transformed into E. coli M15 (pREP) and cultures were grown to an OD600 of 0.9 in 
terrific broth and protein expression induced (3 hr, 37°C) with 1 mM IPTG.  Nickel-
affinity chromatography was used to purify soluble proteins, and purity was determined 
to be >95% by commassie standard SDS-PAGE gel (not shown).   
 
T. brucei blood stream form (BSF) viability assay.  To determine the impact of TbHK1 
inhibitors on cell growth, 5 x 103 BSF parasites (cell line 90-13, a 427 strain) were seeded 
into 96-well clear-bottomed polystyrene plates in HMI-9 supplemented with 10% fetal 
bovine serum and 10% Serum Plus (Sigma-Aldrich, St. Louis, MO) and grown for 3 days 
in 5% CO2 at 37oC grown.  CellTiter Blue (Promega, Madison WI) was added to a final 
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concentration of 16% (v/v) and the plates incubated an additional 3 hours under standard 
culture conditions.  Fluorescence emission at 585nm was then measured after excitation 
at 546nm in a GENios microtiter plate reader (Phenix Research Products, Hayward CA).  
DMSO is tolerated by BSF parasites and has minimal impact on the assay described here, 
with 1% DMSO (f.c.) causing a 16% reduction in cell number at the end of the three day 
assay.   
PF parasites (29-13, a 427 strain, 5 x 104/well) were grown in 96-well clear-
bottomed polystyrene plates in grown in SDM-79 for 2 days (5% CO2, 25oC) and then 
CellTiter Blue added.  Plates were then incubated for 1 hour under standard culture 
conditions.  Fluorescence of samples was then characterized as above.   
 
Mammalian cell-line and Leishmania major promastigote specificity assays.  Cell-
based specificity assays were performed as previously described (Sharlow et al., 2009).  
Briefly, mammalian cell line and L. major promastigote assays were performed in final 
volumes of 25 µL using our previously described 384-well microtiter format (Sharlow et 
al., 2008).   All mammalian cell lines were cultured and maintained in complete growth 
medium preparations according to ATCC specifications (ATCC, Manassas, VA).   L. 
major promastigotes were cultured as previously described (Sharlow et al., 2009).  A549 
(1,000 cells/22 µL), IMR-90 (1,000 cells/22 µL), HeLa (1,000 cells/22 µL), MDA-MB-
231 (3,000 cells/22 µL), L. major promastigotes (5,000 parasites/22 µL) were seeded into 
each well of 384-well microtiter plates and test and control compounds were added to 
individual wells.  Vehicle and positive controls were 1% and 10% DMSO, respectively.  
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For mammalian cells, assay plates were incubated for 44-46 h at 37oC in the presence of 
5% CO2.and for the L. major promastigotes, assay plates were incubated for 44 h at 28oC 
with 5% CO2.  Five µL alamar blue reagent were added to each assay plate well and 
incubated for 2-4 h at 37oC with 5% CO2.  Data were captured on a Molecular Devices 
SpectraMax M5 (excitation A560; emission A590).   
 
HTS data analysis and statistical analysis.  Primary HTS data analysis and subsequent 
compound IC50 calculations were performed using ActivityBase (IDBS, Guilford, UK) 
and Cytominer (University of Pittsburgh drug Discovery Institute, Pittsburgh, PA).  
Structural similarity of the confirmed inhibitors was determined using Leadscope 
software (Columbus, OH).  Additional visualization and statistical analysis were 
performed using GraphPad Prism software 5.0 and Spotfire (Somerville, MA).  The 
PubChem database (http://PubChem.ncbi.nim.nih.gov) was datamined to determine if the 
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Fig. 1.   Validation of the HTS by LOPAC screening.  (A.) Plot of % inhibition for 
duplicate screen of the 1280 LOPAC compounds.  (B.) The LOPAC screen yielded a 
compound similar to a known inhibitor.  Quercetin, a flavonol that inhibits mammalian 
HKs (REF), also inhibits TbHK1 (Lyda and Morris, unpublished).  A structural relative, 
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Abstract   
The majority of the glycolytic enzymes in the African trypanosome are associated with 
peroxisome-like organelles, the glycosomes.  Polypeptides harboring peroxisomal 
targeting sequences (PTS type 1 or 2) are targeted to these organelles.  Here, we have 
found that a trypanosomal hexokinase, TbHK2, which has a PTS2, localized to both 
glycosomes and to the flagellum.   Evidence included fractionation studies and 
immunofluorescence assays of both cells and cytoskeletal preparations using antibodies 
generated to the C-terminal tail of TbHK2.  In addition to flagellar localization, the 
protein co-localized with basal bodies as revealed by localization of an HA epitope-
tagged version of TbHK2.  Comparison of the sequences of several known and predicted 
flagellar proteins with the sequence of TbHK2 revealed a shared hexameric amino acid 
sequence (RAVLAK in the TbHK2) that can direct GFP to the flagellum.  These findings 
suggest that TbHK2 is positioned in the flagellum to perform a task distinct from 
glycosomally-compartmentalized glycolysis.  
 






In the African trypanosome, Trypanosoma brucei, glycolytic enzymes have been 
localized to peroxisome-like organelles called glycosomes (Opperdoes and Borst, 1977).  
This organization, which is thought to serve as a means of regulation of the pathway 
(Haanstra et al., 2008), is unusual as glycolysis is a cytosolic event in most cells.  Even in 
systems with cytosolic glycolysis, glycolytic enzymes have been found in subcellular 
compartments distinct from the cytoplasm.  These include such diverse compartments as 
the sarcoplasmic reticulum in rabbit muscle tissue (Xu and Becker, 1998) and the 
Toxoplasma gondii apicoplast (Fleige et al., 2007).  
A number of species also localize glycolytic and other metabolic enzymes near the 
flagella.  Chlamydomonas reinhardtii has three glycolytic enzymes (phosphoglycerate 
mutase, enolase, and pyruvate kinase) associated with flagellum to produce ATP 
(Mitchell et al., 2005).  In mammals, a hexokinase (HK) has been found attached to the 
fibrous sheath that surrounds the axoneme and outer dense fibers of sperm flagellum, 
suggesting a role in extramitochondrial energy production (Miki et al., 2004; Nakamura 
et al., 2008; Travis et al., 1998).  
Kinetoplastid metabolic enzymes have also been found proximal to the flagellum.  
For example, three isoforms of adenylate kinase localize to either the flagellar axoneme 
or paraflagellar rod (PFR) via an N-terminal extension in the proteins (Ginger et al., 
2005).  Additionally, a Leishmania HK (which was characterized as a hemoglobin 
receptor) has been localized to the flagellar pocket, suggesting that proteins may serve 
multiple functions depending upon localization (Krishnamurthy et al., 2005).   
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 The T. brucei genome encodes two 98 % identical HKs (TbHK1 and TbHK2) that 
are expressed in both bloodstream form (BSF) and procyclic form (PF) parasites.  These 
polypeptides form hexamers that in vitro have distinct biochemical properties depending 
on the ratio of TbHK1 and TbHK2 included in the oligomers (Chambers et al., 2008b).  
Proteomic analysis of purified glycosomes has revealed that both proteins are detectable 
in BSF and PF glycosomes, a finding that supports the observation that over-expression 
of TbHK2 tagged with a C-terminal GFP localizes to the glycosome (Colasante et al., 
2006; Morris et al., 2006).  While the function of theses polypeptides is currently unclear, 
genetics-based studies have confirmed that both are essential to BSF parasites (Albert et 
al., 2005; Chambers et al., 2008a). 
The glycosomal localization of the TbHKs has been attributed to the presence of N-
terminal peroxisomal targeting sequences (PTS2) in both proteins.  This sequence has 
been shown to be responsible for the import of other glycosomally-targeted proteins 
(Blattner et al., 1995), so glycosomal localization of TbHKs was anticipated.  Here, 
however, we report the unexpected dual localization of TbHK2 to both the glycosome 
and flagellum.  The flagellar localization is the result, in part, of a C-terminal targeting 
sequence, found in both TbHK1 and 2, that is conserved in both described flagellar 
resident proteins and hypothetical proteins thought to have flagellar localization.   
 
Materials and Methods 
Subcellular Fractionation and cytoskeletal extraction of trypanosomes – Subcellular 
fractionations were performed using BSF and PF T. brucei  (cell line 449 (Biebinger et 
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al., 1997)), that were constitutively expressing the tetracycline repressor gene (Tet) from 
the chromosomally integrated plasmid pHD449, which also endows phleomycin 
resistance.  This cell line is metabolically indistinguishable from the wild type.  BSF 
parasites were cultured in HMI-9 medium containing 10% heat-inactivated foetal calf 
serum (Invitrogen) and 0.18 μg·mL-1 phleomycin (Cayla) at 37°C under water-saturated 
air with 5% CO2.  Procyclic trypanosomes were grown in SDM-79 medium (Brun and 
Shonenberger, 1979) supplemented with 15% foetal calf serum and 0.5 µg·mL-1 
phleomycin at 28°C under water-saturated air with 5% CO2.  Cultures were always 
harvested in the exponential growth phase, i.e., at densities lower than 2·106 cells·mL-1 
for bloodstream forms and 2·107 cells·mL-1 for procyclic cells, by centrifugation at 700 x 
g for 10 min. 
Localization of glycosomal enzymes was studied by subcellular fractionation of 
cells by treatment with increasing concentrations of digitonin.  Bloodstream (108 cells) 
and procyclic trypanosomes (2 x 108 cells) were washed twice in ice-cold buffer (25 mM 
HEPES, pH 7.4, 250 mM sucrose and 1 mM EDTA), and then resuspended in 0.5 mL of 
the same buffer. The cell suspension was divided in aliquots each containing 100 µg of 
protein and HBSS buffer (Invitrogen) was added to adjust each volume to 100 µL. 
Digitonin, dissolved in dimethylformamide, was then added followed by incubation for 4 
min at room temperature. Untreated cells and those completely lysed (total release, 
generated by incubation in 0.5% Triton X-100) were used for comparison.  After 
centrifugation of the suspensions (12,000 ×g for 2 min), the supernatant (released 
fraction) was probed by western blotting for glycosomal resident proteins.  For detection 
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of the proteins, rabbit polyclonal antisera raised against T. brucei pyruvate kinase (PYK, 
antiserum used at a dilution of 1:100,000), hexokinase (HK, at 1: 100,000), enolase 
(ENO, at 1:150,000) and glycerol kinase (GK, at 1:100,000) were used and detected with 
anti-(rabbit IgG) conjugated to horseradish peroxidase (Rockland Immunochemicals) that 
was visualized using the ECL Western Blotting System (Pierce). 
Cytoskeleton preparations were produced from the addition of Voorheis’s 
modified PBS (vPBS; 137 mM NaCl, 3 mM KCl, 16 mM Na2HPO4, 3 mM KH2PO4, 46 
mM sucrose, 10 mM glucose, pH 7.6) washed cells with either 0.25% NP 40 in 100 mM 
PIPES, pH 6.8 with 1mM MgCl2 or 0.5% Triton X-100 in MME (10 mM MOPS, 2 mM 
EGTA and 1 mM MgSO4) buffer as described (Robinson et al., 1991).  After 5 min, 
cytoskeleton preparations were washed with buffer without detergent.  Cytoskeleton 
preparations were then visualized after adhering to poly-lysine coated slides or left in 
solution for hexokinase assays. 
 
Immunolocalization and western blotting of TbHK2 -  Immunofluorescence assays were 
performed using a protocol modified from (Field et al., 2004).  In short, parasites were 
harvested by centrifugation at 800 x g, washed with vPBS, and then fixed (10 min on ice 
(BSF) or 1 hr on ice (PF)) in an equal volume of 6% paraformaldehyde and vPBS.  Cells 
were washed with vPBS, allowed to settle on poly-lysine slides for 20 minutes, and then 
permeablilized with 0.1% Triton X-100 in PBS (137 mM NaCl, 3 mM KCl, 16 mM 
Na2HPO4, 3 mM KH2PO4) for 10 minutes.  After washing in PBS, block (1% BSA and 
.25% Tween in PBS) was added (1 hr, RT), followed by addition of primary affinity-
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purified TbHK2 polyclonal antibodies (1:1 or 1:10), which were raised against a peptide 
corresponding to the C-terminal end of TbHK2 (CGVGAALISAIVADGK) (Morris et al., 
2006).  Basal bodies were detected using a monoclonal antibody raised against the 
tripartite attachment complex (MAB 22), which lies very close to basal bodies 
(Bonhivers et al., 2008).  This antibody stains both the mature and pro-basal body.  The 
monoclonal antibody MAB 25 was used to detect the axoneme (Absalon et al., 2007).  
GFP was detected using a mouse monoclonal antibody (3E6 GFP, Molecular Probes, 
Eugene, OR, 1:200) and glycosomes localized using a rabbit anti-T. brucei glycosomal 
antibody (2841D, (Parker et al., 1995)) raised primarily against the glycosomal proteins 
pyruvate phosphate dikinase, aldolase, and glyceraldehyde phosphate dehydrogenase 
(Parker et al., 1995) (the kind gift of Dr. Marilyn Parsons (Seattle Biomedical Research 
Institute, Seattle WA)).  Primary antibodies were detected with FITC-conjugated goat 
anti-mouse antibodies or TexasRed-conjugated goat anti-rabbit (1:100, Rockland, 
Gilbertsville PA) secondary antibodies and visualized on a Zeiss Axiovert 200M using 
Axiovision software version 4.6.3 for image analysis. Live PF parasites expressing GFP 
were harvested by centrifugation (800 x g, 5 min), washed with vPBS, and then 
resuspended in an equal volume of vPBS and mounting media with DAPI.   
Western blotting was performed on proteins resolved by 10% SDS-PAGE 
followed by transfer to a nitrocellulose support.  The membrane was incubated in block 
(1% non-fat milk, 10 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.05% Tween-20) and either 
mouse anti-RGS-His6 antibody (Qiagen, Valencia, CA) or TbHK2 antibody added 
(1:2000 or 1:20) in block.   After washes, primary antibody was detected with horseradish 
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peroxidase-conjugated secondary antibody (1:10,000) in block.  Membranes were 
developed using SuperSignal West Pico chemiluminescent substrate (Pierce 
Biotechnology, Inc., Rockford, IL).   
 
DNA constructs for fusion protein expression -  In order to explore the role of putative 
flagellar targeting sequences that impact localization, pXSGFP (Marchetti et al., 2000) 
was modified.  First, the primers FAldoPTS 
(AGCTTATGAGTAAGCGTGTGGAGGTGCTTCTTACACAGCTTG) and RAldoPTS 
(CTAGCAAGCTGTGTAAGAAGCACCTCCACACGCTTACTCATA) were annealed 
and ligated into pXSGFP to produce pXSAldoPTSGFP.  This construct fuses the T. 
brucei aldolase gene PTS2 upstream of GFP.  To engineer putative flagellar targeting 
sequences downstream of the GFP in pXSAldoPTSGFP, the C-terminal 34 residues of 
TbHK1 or TbHK2 (including 10 amino acids upstream of the RAVLAK sequence 
through the end of TbHK1 or TbHK2) was amplified using the primer set 
FHKCtermFsigSphI (GATCGCATGCAACCGTATCCTTGGCC) and 
RHK1CtermFsigEcoRI (GATCGAATTCTTACTTGTCGTTCACC) or 
RHK2CtermFsigEcoRI (GATCGAATTCTCACTTCCCGTCAGCA).  After ligation to 
GFP lacking a stop codon (generated using FGFPNheI 
(GATCGCTAGCGTGAGCAAGGGCGAGGAGC) and RGFPnostopSphI 
(GATCGCATGCCTTGTACAGCTCGTCC)), the construct was introduced into 




Mutagenesis of the RAVLAK sequence to RAGGGK was performed with a 
Quickchange II site directed mutagenesis kit (Stratagene, Cedar Creek TX) using a 
primer set for TbHK1 (GATGTCAGGGCCGGTGGCGGAAAGGATGGCAGT and 
ACTGCCATCCTTTCCGCCACCGGCCCTGACATC) and TbHK2 
(GATGTCAGGGCCGGTGGCGGAAAGGGTGGCAGT and 
ACTGCCACCCTTTCCGCCACCGGCCCTGACATC).   The mutagenesis was used on 
pXSAldoPTSGFPHKCterm, pLewHK2HA, and pQE30TbHK1 to produce 
pXSAldoPTSGFPHKCtermGGGmut, pLewHK2HAGGGmut, and pQE30TbHK1GGG 
respectively.   
Expression of HA tagged TbHK2 was performed by fusing the HA tag to the C-
terminus of TbHK2 followed by cloning into pLew111(2T7)GFPb (the generous gift of 
Drs. Shawn Motyka and Paul Englund, Johns Hopkins School of Medicine).  PF 29-13 
strain trypanosomes were transformed with linearized DNA and selected as described 
(Wang et al., 2000).  Recombinant TbHK2 expression was induced in PF 29-13 cells 
harboring pLew111(2T7)TbHK2HA by addition of tetracycline (1 mg/ml).  Fusion 
protein harboring an HA tag was detected in immunofluorescence using commercially 
available affinity purified anti-hemagglutinin (HA) epitope tag rabbit antibody (Rockland 
Immunochemicals, Gilbertsville, PA). 
 
Results 
Initial studies on the organization of glycolytic enzymes in T. brucei revealed that most 
TbHK activity was associated with the peroxisome-like organelles, the glycosomes 
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(Misset et al., 1986).  Following completion of genome sequencing, it was recognized 
that T. brucei harbors two 98% identical HKs (TbHK1 and TbHK2) that have putative N-
terminal peroxisomal targeting sequences (PTS2).  These sequences can direct proteins to 
peroxisomes and glycosomes (Blattner et al., 1995).  Indeed, proteomic analysis of 
glycosomes has confirmed that both polypeptides are components of the organelle in PF 
and BSF parasites (Colasante et al., 2006).   
 
Fractionation studies suggest additional extra-glycosomal TbHK localization – The 
functions of TbHK1 and TbHK2 remain a mystery.  Notably, recombinant TbHK1 is 
active as an HK in vitro, while recombinant TbHK2 lacks detectable HK activity and is 
only active when oligomerized with TbHK1 (Morris et al., 2006).   
The presence of a second TbHK, TbHK2, which is inactive in vitro, suggests that 
earlier fractionation studies that followed TbHK activity might have described only the 
compartmentalization of TbHK1.  To further explore TbHK distribution, parasite cellular 
components were fractionated and then analyzed by western blotting using antibodies to 
glycosomal-resident proteins.  These include an antibody that detects both TbHK1 and 2 
(Fig. 1).  While glycerol kinase (GK), a known glycosome-resident protein, is released 
from both BSF and PF parasites at a similar digitonin concentration (~0.5 mg 
digitonin/mg protein), other glycolytic enzymes including TbHK release under different 
conditions in BSF and PF cells.  In BSF parasites, TbHK and pyruvate kinase (PK) are 
found in the supernatant at ~0.01 mg digitonin/mg protein, co-fractionating with the 
cytosolic enolase (ENO) protein (Fig. 1A) (Hannaert et al., 2003).  PF parasites release 
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HK and GK at a similar digitonin concentration, while cytosolic ENO is still released 
very early. 
Unanticipated distribution of TbHKs has also been observed by proteomic 
analysis of cell fractions (Personal communication, Dr. Philippe Bastin, Pasteur Institute).  
TbHK2 peptides were identified in both a cell body fraction and also a flagellar fraction.  
While most glycosomal enzymes were under-represented in the flagella fraction, TbHK2 
was modestly enriched (~2-fold), versus a ~6-fold enrichment for described flagellar-
resident proteins.   
 
Immunofluorescence studies of TbHK2 localization suggest multiple localizations – 
Using an affinity purified polyclonal antibodies generated to the proximal C-terminal tail 
of TbHK2 yielded prominent labeling of the both BSF and PF flagellum, while labeling 
of glycosomes was more diffuse (Fig. 2A).  To assess the impact of sample preparation 
on these observations, cells were blocked with either 20% FBS or 1% BSA supplemented 
with 0.25% Tween-20, which resulted in similar stain distribution (data not shown).  To 
confirm that the signal was not due to a contaminating host antibody, anti-sera was 
generated in mice using the same antigen, again yielding primarily flagellar signal with 
diffuse glycosomal staining (Fig. 2A, lower image).  While flagellar staining is clear, 
glycosomal staining is not as readily obvious, though a single image from a Z stack (Fig. 
2B, upper image) layer reveals punctate staining reminiscent of glycosomal staining (Fig. 
2B, lower image).   
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Additional experimental controls were pursued to reduce the likelihood of artifact.  
First, excess peptide antigen was included during primary antibody incubation, which 
eliminated flagellar signal (not shown).  Additionally, RNAi of TbHK2 reduced the 
flagellar signal, though we are hesitant to over-interpret these results due to the 
pleiotropic (and toxic) effect of silencing TbHK2 in BSF parasites (Albert et al., 2005; 
Chambers et al., 2008a).    
 
Cytoskeletal association of TbHKs – The association of signal with the flagellum led us 
to consider whether the staining would be preserved in cytoskeletal fractions.  Upon 
detergent extraction of PF cells, TbHK2 signal localization was found in foci proximal to 
the kinetoplast DNA (Fig. 3A).  Additional faint signal was detectable associated with 
both the flagellum and the nucleus.  The weak flagellar signal, likely due to washing out 
of much of the antigen, suggests TbHK2 is not tightly associated with flagellar 
components while nuclear localization may be an artifact of the detergent extraction that 
allows TbHK2, which has a pI of ~9.1, to bind to DNA.  Co-staining with antibodies to 
the axoneme [MAB 25, (Pradel et al., 2006)] suggests that TbHK2 labeling occurs 
primarily at the terminus of the axoneme (Fig. 3A).  This structure is likely the basal 
body, as anti-basal body antibodies [MAB 22, (Bonhivers et al., 2008)] co-localize with 
anti-TbHK2 signal (Fig. 2B).  Closer inspection (Fig. 3B, inset) indicates that TbHK2 co-
localizes primarily with one of the two basal bodies that flank the kDNA.  Similar results 
were observed using an alternative cytoskeletal preparation method that employs Triton 
X-100 in place of the NP-40 (Robinson et al., 1991).  Western blotting of fractions 
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generated during cytoskeletal preparation supports the microscope-based finding of 
antigen in the cytoskeletal fraction (Fig. 3D). 
To rule out the possibility that the affinity-purified polyclonal anti-TbHK2 
antibodies (both rabbit and mouse) were cross-reacting with a cellular epitope that shares 
features with the C-terminus of TbHK2, we employed reporter epitopes fused to TbHK2 
expressed from an ectopic vector (Fig. 3A).  The inducible expression vector pLew111, 
harboring TbHK2 containing an HA epitope fused to the TbHK2 C-terminus 
(PTSTbHK2HA) was stably transformed into PF parasites and expression scored by IF 
using an antibody to HA.  This epitope tagged TbHK2 also localizes in punctate foci 
(Fig. 3C).  Last, western blotting of cell fractions using anti-TbHK2 antibodies indicates 
a significant portion of cross reacting signal in the cytoskeletal fraction (Fig. 3D, CS), 
though signal is found in the soluble fraction of the cell lysate (Fig 3D, S and longer 
exposure in OS), consistent with enzyme that would be released from glycosomes during 
the cytoskeletal preparations.   
 
Flagellar targeting sequence analysis – How is TbHK2 targeted to the flagellum?  
Comparison of the sequences of several known and predicted flagellar proteins with the 
sequences of TbHK1 and TbHK2 revealed a shared hexameric sequence (RAVLAK in 
the TbHKs) (Fig. 4A).  This sequence overlaps a flagellar targeting motif found in the 
PFRA protein that shares high homology to a region in the dynein b heavy chain of the 
outer arm of Chlamydomonas flagellum (Bastin et al., 1999).  While both T. brucei and T. 
gambiense HKs harbor the hexameric sequence, human glucokinase and the S. cerevisiae 
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HKs lack this sequence, which lies between the HK VI and VII domains common to all 
characterized HKs.  Using a model of the structure of TbHK2 (Morris et al., 2006), the 
hexamer is positioned on an external face of the protein between the large and small HK 
subunits and proximal to the active site (Fig. 4B).   
 
The putative flagellar targeting sequence alters GFP localization - To explore the role of 
the hexameric putative FTS sequence in targeting TbHK2 to the flagellum, we have 
generated GFP fusions with the sequence in live parasites (Fig. 5).  These experiments 
have employed both transient and stable transfection of parasites with the constitutively 
expressed pXSGFP vector.  Expression of GFP alone yielded cytosolic signal (Fig. 5, 
panel A), while expression of an N-terminal PTS-2 (residues 1-12 of T. brucei aldolase)-
bearing GFP led to focusing of the fluorescence into punctate bodies that are consistent 
with glycosomal localization [Fig. 5, panel B, and (Parker et al., 1995)].  Co-localization 
was confirmed using fixed cells probed with anti-GFP and anti-glycosomal antibodies 
(Parker et al., 1995) (data not shown).   When the terminal 34 residues of TbHK2 
(starting ten amino acids upstream of the RAVLAK and extending to the end of the 
TbHK2 ORF) were fused to the C-termini of the PTS2-bearing GFP (to yield 
pXSPTSGFPHKC-terminus), signal was found distributed throughout the cell, but 
partially localized proximal to the flagellum (Fig. 5, panel C, indicated by the arrows).  
This localization is not as clear as that provided with the TbHK2 antibody, perhaps 
because the construct contains only a portion of the TbHK2 sequence (the overall context 
in which the RAVLAK is presented possibly influences targeting).  Notably, altering the 
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RAVLAK sequence (to RAGGGK) changes the over-all localization (Fig. 5, panel D), 
with signal limited to glycosomes.  However, altering the RAVLAK sequence to 
RAGGGK does not impact the catalytic properties of recombinant TbHK1 (not shown), 
suggesting that in vitro folding is not dramatically altered in the RAGGGK variant. 
 The FTS from characterized and presumptive flagellar proteins, including TbPFR-
A, is not a C-terminal extension, but rather is an internal signal sequence (Fig. 4A).  
Fusion of the putative TbHK FTS hexamer to the C-termini of PTS2-bearing GFP 
indicates that this rule holds true for the TbHKs, as fluorescence from this construct is 
limited to glycosomes (not shown).  This observation suggests that the environment in 
which the RAVLAK is situated is important for imparting flagellar localization. 
 
Discussion 
The association of glycolytic proteins with flagellum is not without precedence, as 
enzymes involved in glucose metabolism have been found in the flagellum from a range 
of organisms, including green algae and mammals (Mitchell et al., 2005; Travis et al., 
1998).  The role of these proteins has primarily been postulated to be in the production of 
energy for the flagellum.  Is TbHK2 serving a similar role in the trypanosome flagellum?  
TbHK2 is competent for HK activity when organized with TbHK1 into oligomers 
(Chambers et al., 2008b), although it is not known if TbHK1 is also found in the parasite 
flagellum in a position to interact with TbHK2.  Notably, the polyclonal antibody raised 
against the C-terminal tail of TbHK2, while specific to the denatured TbHK2 antigen (as 
determined by western blotting, (Morris et al., 2006)), may cross-react with both native 
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TbHK1 and TbHK2.  The native C-terminal epitope is predicted to form an α-helix with 
one face of the helix being identical in both TbHK1 and 2, suggesting that the polyclonal 
antibody may recognize that common feature in native proteins.  This suggestion is 
supported by cross-reacting flagellar signal detected in cell lacking TbHK2 [TbHK2-/-, 
(Morris et al., 2006), data not shown] and by the presence of the conserved FTS in 
TbHK1.   
 If TbHK2 is indeed oligomerized with TbHK1 in the flagellum, it may be playing 
some role in the regulation of TbHK activity [as seen in vitro, (Chambers et al., 2008b)].  
To yield ATP through the activity of TbHKs, this model would require that other 
components of the glycolytic pathway reside near the flagellum (Fig. 6).  Consistent with 
that, pyruvate kinase (this work, Fig. 1), glycerol-3-phosphate dehydrogenase, and 
glyceraldehyde-3-phosphate dehydrogenase (Oberholzer et al., 2007) have all been found 
associated with the trypanosome flagellum.  Alternatively, flagellar TbHK2 may 
participate in the metabolism of sugar nucleotides to generate ATP – an activity that has 
been demonstrated in vitro with other HKs (Gamble and Najjar, 1955), but which 
remains undetected with recombinant TbHKs. 
TbHK2 may not be limited to a metabolic function in the flagellum, but rather the 
protein may play a role in glucose sensing in the flagellum.  Glucokinases and HKs from 
other systems, including yeast, plants, and animals, have all been shown to be central in 
conveying information to the cell regarding environmental glucose availability that allow 
the cell to respond (Rolland et al., 2001).  In other kinetoplastids, hexose transporters 
have been found associated with the flagellum (Snapp and Landfear, 1999), suggesting 
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that uptake of glucose may occur proximal to the flagellar positioning of TbHK2, 
positioning it to serve in an environmental glucose sensing role.  In T. brucei, signaling 
enzymes associated with the flagellum is not without precedence, as an adenylate cyclase 
(ESAG4) has been found proximal to the flagellum in both PF and BSF parasites 
(Paindavoine et al., 1992). 
 Cell fractionation studies suggest that extra-glycosomal localization of TbHK2 
(and PK) is limited to the BSF lifecycle stage (Fig. 1).  This data appears to contradict the 
IFA data of PF parasites stained with the TbHK2 polyclonal antibody, which yields both 
glycosomal and flagellar signal (Fig. 2).  Differences in the relative abundance of the 
protein in the two compartments between the two lifecycles may explain this, as the 
intensity of glycosomal staining is greater in PF parasites than BSF parasites.  This 
suggests that the total distribution of TbHK2 is different between the two lifecycle stages, 
with the protein being predominantly flagellar in BSF parasites while being mostly 
glycosomal in PF parasites.   
Previously, we found that TbHK2 expressed in PF parasites with a GFP C-
terminal fusion was glycosomally localized (Morris et al., 2006).  While the bulky GFP 
reporter likely interferes with the C-terminal FTS (see Fig. 4 for positioning of the FTS), 
this observation raises the possibility that TbHK2 flagellar localization requires an 
obligate transit step through the glycosome.  PTS2 deficient HKs tagged with fluorescent 
proteins are cytosolic (data not shown), supporting this suggestion.  Potentially adding to 
the complexity of targeting to the flagellum, the unusual hexamerization of TbHKs, 
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which is dynamic and subject to environmental cues (Chambers et al., 2008b), may 
influence localization.    
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Figure 1. Subcellular distribution of glycolytic enzymes analyzed by digitonin-dependent 
cell fractionation.  Intact bloodstream and procyclic-form trypanosomes were incubated 
for 4 min with increasing concentrations of digitonin indicated as described in the 
Materials and Methods.  Release of enolase (ENO), glycerol kinase (GK), hexokinase 
(HK), and pyruvate kinase (PYK) from BSF (A.) or PF (B.) cells were assayed after 
centrifugation of treated cell suspensions and preparation of western blots of the 
supernatants.  Total release (T.R.) lanes correspond to cells incubated with 0.5% Triton 
X-100 to solubilize all membranes. 
 
Figure 2. Flagellar localization of TbHK2 in BSF and PF parasites.  (A) 
Immunofluorescence using affinity-pure polyclonal sera from mouse (top) or rabbit 
(bottom) that had been immunized using the C-termini of TbHK2 as antigen.  BSF 90-13 
or PF 29-13 were fixed, permeabilzed, and stained with primary antibodies (1:1), which 
were detected with FITC (green)-conjugated goat anti-mouse or mouse anti-rabbit 
antibodies, respectively.  DAPI (blue) was added with anti-fade reagent to stain the 
nucleus and kDNA.  (B) A Z-stack of TbHK2 stained BSF 90-13 cells was captured and 
an extended focus image was produced to show the signal throughout the parasite (top).  
To illustrate glycosome-like bodies (arrows), which are lost when an extended focus 
image is produced from the Z-stack layers, a single Z-stack layer (bottom) is included. 




Figure 3. Immunofluorescence of PF cytoskeleton preparations reveal TbHK2 
association with the basal body.  (A) PF cytoskeletons were stained with affinity-purified 
rabbit antibodies against TbHK2 (red) and a mouse monoclonal antibody to the axoneme 
(MAB 25, green (Absalon et al., 2007)), and texas red or FITC-conjugated species-
specific secondary antibodies used to visualize localization.  (B) Dual 
immunofluorescence of PF cytoskeleton preparations using the affinity-purified rabbit 
TbHK2 antibodies (red) and Mab22 (a monoclonal antibody raised against the tripartite 
attachment complex, which lies near the basal bodies, green (Bonhivers et al., 2008)).  
The boxed region was enlarged in the image below each figure to more readily view 
basal body and TbHK2 co-localization.  The overall signal is reduced for the anti-TbHK2 
staining, in part due to the alteration to fix and block schemes required for Mab22 
localization.  (C) Immunoflourescence of cytoskeletons from PF29-13 parasites induced 
to over-express TbHK2 with a C-terminal HA tag from pLew111(2T7)TbHK2HA.  The 
HA tag was detected using an affinity purified anti-hemagglutinin (HA) epitope tag rabbit 
antibody (Rockland Immunochemicals, Gilbertsville, PA) diluted 1:1000 in block (1% 
BSA, 0.25% Tween in 1 x PBS) The scale bar = 10 mm throughout this figure.  (D) 
Western blot of PF cytoskeleton preparation. The lanes are as follows: CS – cytoskeleton 
fraction, S – supernatant of cytoskeleton preparation, WC – whole cells, rTbHK2 – 
recombinant TbHK2 protein, and OS – over-exposure of the supernatant lane.  
 
Figure 4. TbHKs harbor a sequence that is conserved in other known and predicted 
flagellar proteins.  (A.) Alignment of TbHK1 and TbHK2 FTS with known and 
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hypothetical flagellar proteins using Clustal W1.8 from MyHits SIB (Swiss Institute of 
Bioinformatics). (B) The TbHK2 model (based on the yeast crystal structure (Chambers 
et al., 2008c), with the peroxisomal targeting 2 sequence (PTS2), putative FTS, and 18 
residue carboxy terminus noted.  
 
Figure 5. The putative FTS directs GFP to extraglycosomal localizations, including the 
flagellum.  (A) PF2913 parasites harboring pXSGFP express GFP from a constitutively 
active transgene.  (B) Expression of GFP with the PTS2 sequence from T. brucei aldolase 
(pXSAldoPTSGFP). (C) GFP harboring an N-terminal aldolase PTS2 fusion and a C-
terminal fusion to the terminal 34 residues of TbHK2 (TbHK2pXSAldoPTSGFPHKC-
terminus). The flagellum is indicated by the white arrow. (D) A variant GFP harboring 
the N-terminal PTS2 and a mutated version of the terminal 34 residues of TbHK2 (VLA 
to GGG), expressed from pXSAldoPTSGFPHKC-term mut.  The scaled bar = 10 µm.   
 
Figure 6.  Schematic illustrating possible functions of TbHK2 while proximal to the 
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The use of TbHK inhibitors as drug therapies for HAT is still under development. 
However, great strides in target-driven drug development have been accomplished. The 
efficacy of TbHK inhibitors against HAT has been demonstrated against in vitro parasite 
culture, but more work including in vivo parasite experiments will need to be completed 
to confirm the value of these compounds as therapeutic leads. The ability of a compound 
to kill parasites in culture does not directly correlate with the same compound’s ability to 
kill parasites found within a mammalian host. Problems including delivery difficulties as 
a consequence of solubility and toxic side-effects can arise when in vivo studies are 
performed. 
There are many unusual questions that arise from the finding of TbHK2 in the 
flagellum. These include: How does TbHK2 localize to the flagellum? The putative 
flagellar targeting sequence found on TbHK1 and TbHK2 may be involved in flagellar 
localization but the route to the flagellum is still unknown. What role does TbHK2 play 
in the flagellum? TbHK2 could act as a functional hexokinase, TbHK2 could work in the 
reverse reaction to generate ATP or TbHK2 could be an environmental glucose sensor in 
the flagellum. Does TbHK2 have a different role in the flagellum than its role in the rest 




The future is promising for finding a role of TbHK2. TbHK2 may be a vital target 
for HAT therapies just as TbHK1 has shown very promising results. A therapy for HAT 
may prove most effective when both TbHK1 and TbHK2 activities are disrupted. 
If I was to continue my work at Clemson University, I would attempt to observe 
the localization of TbHK1. I find it intriguing that both TbHKs have a PTS2 and a FTS. 
The localization of TbHK1 may elucidate the role of TbHKs in the flagellum even 
further. Also, I would take the HTS to the next step, mice. The ability of the compounds 
to kill parasites may be different when observing cell death in culture versus within a 
mammalian host. And if a compound is found to be promising then pharmacology work 
would need to be conducted to be able to treat HAT patients. 
Overall, the parasite T. brucei is an exciting organism to perform research into the 
realm of biology but the true focus of the research should never be forgotten. The people 
of sub-Saharan Africa are still influenced by the occurrence of T. brucei. In time there 
will be a solution to the problem. Unfortunately the work is not fast enough. People are 
dying today. All that is left is the burning question: Will the future ever hold a day when 
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The African trypanosome, Trypanosoma brucei, can gauge its environment by sensing 
nutrient availability.  For example, procyclic form (PF) trypanosomes monitor changes in 
glucose levels to regulate surface molecule expression, which is important for survival in 
the tsetse fly vector.  The molecular connection between glycolysis and surface molecule 
expression is unknown.  Here we partially characterize T. brucei homologs of the β and γ 
subunits of the AMP-activated protein kinase (AMPK), and determine their roles in 
regulating surface molecule expression.  Using flow cytometry and mass spectrometry, 
we found that TbAMPKβ or TbAMPKγ-deficient parasites express both of the major 
surface molecules, EP- and GPEET-procyclin, with the latter being a form that is 
expressed when glucose is low such as in the tsetse fly.  Last, we have found that the 
putative scaffold component of the complex, TbAMPKβ, fractionates with organellar 
components and colocalizes in part with a glycosomal marker as well as the flagellum of 
PF parasites.  
 








Trypanosoma brucei, the protozoan parasite that causes African sleeping sickness, is a 
hemoflagellate that is transmitted to its mammalian host by the bite of an infected tsetse 
fly.  In the mammalian infection, trypanosomes proliferate within the blood as long 
slender forms and can differentiate into short stumpy forms that are pre-adapted for life in 
the insect.  When the insect ingests short stumpy trypanosomes during a blood meal, the 
parasites differentiate into procyclic form parasites (PF1) in the fly midgut (Vickerman, 
1985).  After about 3 weeks, they are found in the salivary glands where they develop 
into metacyclic forms that are infectious to mammals.  
The PF parasites are covered by a coat consisting of members of the procyclin 
family of glycoproteins (Matthews and Gull, 1994, Roditi, et al., 1989, Ziegelbauer, et 
al., 1990).  The GPI-anchored procyclins, EP-procyclins and GPEET-procyclin, have at 
their C-terminus 22-30 Glu-Pro repeats (EP-procyclin) or five or six Gly-Pro-Glu-Glu-
Thr repeats followed by three EP repeats (GPEET-procyclin) (Mowatt and Clayton, 
1987, Mowatt, et al., 1989, Richardson, et al., 1988, Roditi, et al., 1987).  The different 
isoforms of procyclins have different features.  For example, EP1-1, EP1-2, and EP3 are 
N-glycosylated with a homogeneous Man5GlcNAc2 while EP2 is unglycosylated (Acosta-
Serrano, et al., 1999, Hwa, et al., 1999, Treumann, et al., 1997).  GPEET is 
unglycosylated but is phosphorylated at the threonine residues (Butikofer, et al., 1999, 
Mehlert, et al., 1999).  Expression of procyclins can be influenced by culture conditions 
in vitro.  Glycerol in the culture medium triggers GPEET expression, as can growth in 
glucose-depleted (~ 0.03 mM) medium (Butikofer, et al., 1997, Morris, et al., 2002, 
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Treumann, et al., 1997).  Early in the in vitro differentiation of bloodstream forms to PFs, 
both types of procyclins are expressed (Vassella, et al., 2001).  GPEET expression 
increases in the first 24 hours, to be replaced by glycosylated EP-procyclins later in 
development (Vassella, et al., 2001). A similar program of expression has been observed 
in parasites isolated from tsetse fly infections, though insufficient parasites were available 
for analysis prior to day 3 of the infection (Acosta-Serrano, et al., 2001, Vassella, et al., 
2000).  Although the function of the different procylin isoforms remains to be determined 
(Vassella, et al., 2009), it is suggested that its polyionic nature may help the parasite to 
resist attack by tsetse midgut proteases (Acosta-Serrano, et al., 2001). 
Previously, we screened an RNAi-based genomic library for cells resistant to the 
lectin concanavalin A (Con A), which binds the N-glycan on EP-procyclins and induces 
cell death (Hwa, et al., 1999, Pearson, et al., 2000, Welburn, et al., 1996).  We found that 
glycolysis (or the rate of glycolytic flux) was a regulator of procyclin expression.  Under 
conditions in which the rate of glycolysis was reduced, EP-procyclin expression was 
repressed, while GPEET-procyclin expression was upregulated. 
  Complicating the connection between glucose metabolism and surface molecule 
expression is the compartmentalization of a majority of glycolysis in peroxisome-like 
organelles, the glycosomes.  This compartmentalization suggests that some extra-
glycosomal metabolic sensor may be involved in the transmission of information about 
glycolysis to the nucleus.  To resolve the components that connect glucose metabolism 
and surface molecule expression, we have used reverse genetics to characterize genes that 
were predicted to be involved in glucose sensing based on observations from other 
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systems.  In other organisms, AMP-activated kinase (AMPK), a heterotrimeric enzyme 
complex consisting of α, β, and γ subunits, is a key regulator in nutrient sensing 
(reviewed in (Carling, 2004)).  The a subunit contains a kinase domain as well as a 
regulatory domain that inhibits the enzyme in the absence of AMP (Crute, et al., 1998).  
The β subunit acts as a scaffold for the other components, while the γ subunit is thought 
to be involved in AMP binding (Cheung, et al., 2000). 
 AMPK is a member of the AMPK/SNF1 family, which has been described in 
many eukaryotes (Hardie, et al., 1998, Hardie and Hawley, 2001, Kemp, et al., 1999) and 
acts in nutrient sensing pathways in yeast and mammals.  Under conditions that reduce 
glycolysis, the yeast SNF1 complex (a homolog of AMPK (Carlson, 1999)) is activated.  
This kinase modulates the cellular response to decreased glycolysis by phosphorylating 
(and activating) metabolic enzymes, including glycolytic enzymes such as hexokinase.  
Similarly, low glucose conditions activate mammalian AMPK (Salt, et al., 1998), which 
triggers changes in gene expression, including increase in expression of metabolic genes 
involved in glycolysis (reviewed in (Hardie and Hawley, 2001)).   
While the a subunit remains elusive, we have identified homologous genes for the 
β and γ subunits (TbAMPKb and TbAMPKg, respectively) of the heterotrimeric 
components (α, β, and γ) of AMPK in T. brucei and have explored the role of these genes 
in the regulation of surface molecule expression in response to glucose levels.  Silencing 
these genes triggers changes in surface molecule expression, while localization of the 
scaffold (β) subunit suggests positioning in the cell consistent with a role as an 




MATERIALS AND METHODS 
Trypanosome growth and RNAi.  PF 29-13 T. brucei, a 427 strain that 
expresses T7 RNA polymerase and the tetracycline repressor, were grown in SDM-79 as 
described (Wang, et al., 2000, Wirtz, et al., 1999).  Low glucose SDM-79 was prepared 
with glucose-free RPMI 1640 replacing the liquid MEM.  Also, additional glucose and 
glucosamine (normally present in SDM-79 at 1 mg/ml and 50 ng/ml, respectively) were 
omitted.  This mixture was supplemented with normal FBS (10%), resulting in a final 
glucose concentration of ~ 0.5 mM.  
 RNAi constructs were generated by ligation of TbAMPKβ (276 bp, from nt 436 to 
711 of the open reading frame) or TbAMPKγ (461 bp, from nt 895 to 1356) PCR products 
amplified from T. brucei strain 427 genomic DNA into XhoI/HindIII cut pZJM (Wang, et 
al., 2000).  Parasites (1 x 108) were transformed with 10 mg NotI linearized 
pZJM(AMPKb) or pZJM(AMPKg) and stable integrants selected with phleomycin (2.5 
mg/ml) as described (Wang, et al., 2000).  RNAi was induced by the addition of 
tetracycline (tet, 1 mg/ml) to cultures.   
 
Flow cytometry and surface glycoprotein labeling.  Parasites were labeled with 
fluorescein-conjugated Con A as described (Morris, et al., 2002).  Briefly, cells (1 x 106) 
were resuspended in 1 ml cytomix supplemented with 1 mM MnCl2 (cytoM (van den 
Hoff, et al., 1992)) containing 10 mg/ml FITC-labeled Con A (Sigma, St. Louis, MO).  
After 15 min at room temperature, trypanosomes were applied to a FACScan flow 
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cytometer (Becton Dickinson Biosciences, Franklin Lakes, NJ) and 10,000 cells analyzed 
per sample.  Antibody labeling of surface molecules was performed using 5 x 106 
parasites that were washed in PBS, fixed in 4% paraformaldehyde/0.1% glutaraldehyde 
(12 hr, 4oC), and washed in 1% BSA in PBS (blocking solution).  Antibodies to EP-
procyclin (monoclonal antibody TBRP1/247, Cedarlane Laboratories, Ontario Canada 
(Richardson, et al., 1988, Richardson, et al., 1986)) or GPEET-procyclin (monoclonal 
5H3 (Butikofer, et al., 1999)), which was a generous gift from Dr. Terry Pearson 
(University of British Columbia) were diluted (1:100) and incubated with cells (1hr, 4oC) 
in blocking solution.  Parasites were washed, incubated in FITC-conjugated goat anti-
mouse antibody (1 hr, 4oC in blocking solution), and then resuspended in sheath fluid for 
flow cytometry. 
 
MALDI-TOF-MS analysis of procyclins.  For mass-spectrometry analysis, 
procyclins were purified from freeze-dried parasites (1 x 108) by sequential extraction 
with organic solvents (Acosta-Serrano, et al., 1999). To remove GPI anchors from 
polypeptides, dry butanolic extracts were dephosphorylated with 25 µl of 48% aqueous 
hydrofluoric acid (aq. HF) for 20 h at 0 °C.  After treatment, samples were dried in a 
Speed-Vac and resuspended in 20 µl of 0.1% TFA.  An aliquot (~ 0.5 µl; ~ 5 x 106 
parasite equivalents) was co-crystallized with 0.5 μl 10 mg/ml sinapinnic acid in 70 % 
acetonitrile, 0.1 % TFA and analyzed by positive-ion mode.  Data collection was in linear 
mode on a PerSeptive Biosystems Voyager-DE mass spectrometer (located at the Sir 
Henry Wellcome Functional Genomics Facility, Glasgow University). The accelerating 
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voltage was 2500 V and the grid voltage was set at 91 % with an extraction time delay of 
100 nsec.  Data were collected manually at 200 shots per spectrum, with laser intensity 
set at 2800.  To confirm assignments, HF-treated samples (~5 x 107 parasite equivalents) 
were submitted to mild acid hydrolysis with 40 mM TFA for 20 min at 100 °C, and an 
aliquot analyzed by MALDI-TOF-MS as described above (Acosta-Serrano, et al., 1999). 
 
Digitonin fractionation and Hexokinase assays.  Digitonin fractionation was 
performed using a method adapted from(Lorenz, et al., 1998).  Parasites (1 x 107) were 
washed in cold PBS, followed by a wash in STE buffer (250 mM sucrose, 25 mM Tris, 
pH 7.4, 1 mM EDTA).  Cells were resuspended in STE+N (150 mM NaCl) with 0.1 M 
PMSF, pelleted, and resuspended in STE+N with digitonin (0.2 mg/ml).  The mixture 
was vortexed for 5 min and then incubated at 25oC for 4 min.  Lysates were centrifuged 
(2 min, 15,000 x g, 4oC) and pellets resuspended in 0.1 M TEA, pH 7.5 (5 x 105 cell 
equivalents/ml).   
Hexokinase assays were performed in a coupled assay as previously described on 
equal volumes of the resulting supernatant and pellet from the digitonin fractionation 
(Misset and Opperdoes, 1984, Morris, et al., 2002).  Assays were performed in triplicate 
in 96-well microtiter plate format using a GENios spectrophotometer (Phenix Research 
Products, Hayward, CA). 
 
Localization of TbAMPKβ subunit.  To localize TbAMPKβ, PF parasites 
expressing eYFP fused to the T. brucei aldolase peroxoisomal targeting sequence 2 
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(PTS2, which targets proteins to glycosomes) were harvested by centrifugation at 800 x 
g, washed with Voorheis’s modified PBS (vPBS; 137 mM NaCl, 3 mM KCl, 16 mM 
Na2HPO4, 3 mM KH2PO4, 46 mM sucrose, 10 mM glucose, pH 7.6) and fixed in an equal 
volume of 6% paraformaldehyde and vPBS for 1 hr on ice. Cells were washed with vPBS 
and then allowed to settle on poly-lysine coated slides prior to permeabilization with 
0.1% Triton X-100 in PBS (10 min, RT) and then washed in excess PBS three times 
before the addition of block (1% BSA and 0.25% Tween in PBS, 1 hr, RT).  Primary 
affinity purified rabbit polyclonal antibodies for TbAMPKβ, which was purified using an 
antigen coupled AminoLink Coupling Resin (Thermo Scientific, Rockford Il) following 
the manufacture’s instructions, and a mouse monoclonal against GFP (3E6, Molecular 
Probes, Eugene, OR) were applied at a dilution of 1:10 and 1:100, respectively, for 1 
hour. The slides were washed 3 times in excess PBS before the addition of the secondary 
antibodies (TexasRed-conjugated goat anti-rabbit and FITC-conjugated goat anti-mouse; 
Rockland, Gilbertsville, PA, both at 1:100).  Slides were then washed 3 times in excess 
PBS and prepared for visualization by addition of Vectashield mounting media with 
DAPI. Images were taken on a Zeiss Axiovert 200M using Axiovision software version 
4.6.3 for image analysis. 
 To express TbAMPKβ with a C-terminal fusion to GFP in live parasites the 
TbAMPKβ open reading frame was cloned into pLew111(2T7)GFPβ (the generous gift of 
Drs. Shawn Motyka and Paul Englund, Johns Hopkins School of Medicine).  PF 29-13 
strain trypanosomes were transformed with linearized DNA and selected as described 
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above.  Recombinant TbAMPKβGFP expression was induced for 4 days by addition of 
tet (1 mg/ml) and GFP expression monitored by microscopy. 
 
RESULTS 
Identification and silencing of AMPK subunit homologs in T. brucei.  We 
have identified candidate single copy homologous genes for the β and γ subunits 
components of the heterotrimeric enzyme AMPK in the T. brucei genome database.  The 
putative T. brucei AMPKβ subunit (TbAMPKβ systematic name Tb927.8.2450) is 
similar to the rat AMPKβ1 protein (E value = 2.8 x 10-10), sharing 33% amino acid 
identity.  TbAMPKβ is predicted to be a 34.4 kDa protein that contains a 5’ AMP-
activated protein kinase β-subunit complex interacting region (α/γ interaction domain, 
residues 195-303) found in the β subunit of mammalian AMPK and yeast homologs of 
AMPK (Thornton, et al., 1998) (Fig. 1A).  In other systems, this domain allows 
interaction with the kinase (α) subunit and is characteristic of β subunits.  TbAMPKβ also 
shares with the rat AMPKβ1 protein a conserved putative N-myristolyation signal (Fig. 
1A) and two (of four) conserved Ser (at residue 119 and 126) (Carling, 2004).   
The putative T. brucei AMPKγ subunit (TbAMPKγ, systematic name 
Tb10.70.3670) is predicted to be a 55.2 kDa protein that is most similar to human 
AMPKγ3 (E value = 1.1 x 10-11, 27% identical at the amino acid level).  The 
trypanosome protein is predicted to have 4 cystathionine-b-synthase (CBS) domains 
(residues 80-134, 187-244, 361-414, 430-484), which have been found in other γ subunits 
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(but are not limited to AMPKγ subunits) (Fig. 1A).  The CBS domains have been 
implicated to function in AMP binding (Cheung, et al., 2000, Daniel and Carling, 2002).   
To initiate analysis of the function of TbAMPK subunits, we silenced the putative 
subunits using the pZJM RNAi vector.  The impact of RNAi of either subunit on cell 
viability was minimal, causing ~2-fold increase in doubling time (not shown).  Induction 
of RNAi for 40 hours led to a dramatic decrease in TbAMPKβ and TbAMPKγ transcript 
abundance (Fig. 1B) (Wang, et al., 2000).  Due to low transcript abundance, the northern 
blots of TbAMPKβ were particularly difficult to assess.  Since RNAi ultimately leads to 
protein depletion, we used western blotting to confirm the TbAMPKβ knock down using 
polyclonal antibodies to recombinant TbAMPKβ protein after RNAi (Fig. 1C).  The ~ 34 
kDa polypeptide was detectable by western blot from 1 x 106 parental 29-13 cell 
equivalents, while silencing TbAMPKβ led to a ~5-fold reduction in detectable protein 
with 5 x 106 cell equivalents (Fig. 1C, lanes 3 and 4).   
Bioinformatics-based approaches suggested there were 14 active members of the 
CAMK group of kinases in the T. brucei genome, which include the AMPKα subunit 
(Parsons, et al., 2005).  Of these potential a subunits, a candidate T. brucei gene that 
clustered closely with yeast SNF1 and human AMPKα1, Tb10.70.1760.  RNAi of 
Tb10.70.1760 failed to yield a discernable Con A binding phenotype (see below), 
suggesting that we had either identified and tested the incorrect homolog, or that 
functional redundancy was obscuring the resolution of the α subunit.  For these reasons, 




RNAi of TbAMPKβ or TbAMPKγ impacts surface molecule expression. 
Previously, we found through an RNAi-based genomic library screen that glycolysis 
modulated surface glycoprotein expression in PF parasites (Morris, et al., 2002).  
Therefore, we reasoned that knockdown of proteins that play a role in the connection of 
glycolysis to surface molecule expression may yield cells with similar dis-regulation of 
surface molecule expression.   
To determine if TbAMPK subunit silencing leads to this phenotype, we first 
stained TbAMPKβ and TbAMPKγ-deficient cells with the lectin Con A, which 
predominantly binds to glycosylated EP-procyclins but not to GPEET on PF 
trypanosomes (Pearson, et al., 2000) (Fig. 2).  We have used this approach to previously 
characterize the impact of silencing glycolytic enzymes on surface molecule expression 
(Morris, et al., 2002).   The impact of silencing TbAMPKβ and TbAMPKγ on Con A 
binding was assessed in cells grown in standard SDM-79 medium or in reduced glucose 
(~ 0.5 mM) medium for 7 days.  While growth in reduced glucose medium did not alter 
parental PF 29-13 cell Con A-FITC binding (Fig. 2A, light gray line compared to dark 
grey line, and (Morris, et al., 2002)), culturing of TbAMPKβ or TbAMPKγ-deficient 
cells in normal medium caused a subtle reduction in Con A binding while growth in low 
glucose medium for 7 days caused a dramatic reduction in Con A binding (Fig. 2B and 
2C, black line compared to grey line). 
To further characterize the nature of the surface molecule change, we used 
antibodies to the major surface glycoproteins to assess expression by flow cytometry.  
We found that cells deficient in either TbAMPKβ or TbAMPKγ have a similar glucose-
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dependent RNAi phenotype that is not observed in the parental cell line.  Parental 29-13 
PF trypanosomes predominantly expressed EP-procyclin (Fig. 3A, left panel) with little 
detectable GPEET-procyclin (Fig. 3A, right panel).  These findings are in agreement with 
the procyclin repertoire that has been described from PF 29-13 parasites (Acosta-Serrano, 
et al., 1999, Morris, et al., 2002).   
 Like parental PF 29-13 cells, TbAMPKβ-deficient parasites expressed EP-
procyclin (Fig. 3B, left panel) and expressed very little GPEET-procyclin (Fig. 3B, right 
panel).  However, if parasites deficient in TbAMPKβ were grown under reduced glucose 
(~ 0.5 mM) conditions, a greater proportion expressed GPEET-procyclin (Fig. 3B, right 
panel, +tet, -glc).  These cells continued to express EP-procyclin (Fig. 3B, left panel).  
Cells with TbAMPKγ silenced also expressed EP-procyclin (Fig. 3C, left panel) 
and demonstrated a subtle increase in the surface expression of GPEET-procyclin (Fig. 
3C, right panel).  Under reduced glucose (~ 0.5 mM) conditions, a greater proportion 
expressed GPEET-procyclin (Fig. 3C, right panel, +tet, -glc).  Again, these cells 
continued to express EP-procyclin (Fig. 3C, left panel), with both procyclins expressed 
for the duration of these experiments (~14 days).  Addition of glucose to these cells 
blocked the increased expression of GPEET-procyclin (Fig. 3C, right panel, +tet –
glc/+glc).   
 
MALDI-TOF mass spectrometry confirms that normally glycosylated EP-
procyclin, in addition to GPEET-procyclin, is expressed after RNAi of TbAMPKβ or 
TbAMPKγ. Silencing either TbAMPKβ or TbAMPKγ subunits triggered a loss of Con A 
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binding, while antibody staining and flow cytometry analysis of these cells indicated that 
EP-procyclin was expressed on the surface.  These observations seem to conflict, as Con 
A binds to the N-glycan of EP-procyclin.  How is there a reduction in Con A binding 
while the protein to which Con A binds is still expressed?  These data suggested that 
GPEET-procyclin could be masking the N-glycan of EP-procyclin.  Alternatively, EP-
procyclins may not be properly N-glycosylated in the TbAMPKβ or TbAMPKγ-deficient 
cells, or EP-2 (a naturally occurring unglycosylated EP-procyclin) could be the dominant 
EP-procyclin in these cells.  To resolve these possibilities, we performed MALDI-TOF 
mass spectrometry on partially purified procyclins from parental PF 29-13, TbAMPKβ-
deficient, or TbAMPKγ-deficient trypanosomes grown in low glucose medium (Fig. 4).   
Expression of GPEET was confirmed by positive-ion MALDI-TOF-MS on HF-
treated procyclin polypeptides.  Parental PF 29-13 expressed only glycosylated EP-
procyclin species (i.e. EP1-1, EP1-2 and EP3) (Fig. 4A).  Ions representing GPEET (m/z 
6141) or EP2-procyclin (m/z 8345; the only naturally unglycosylated procyclin) were not 
detected, consistent with the Con A and antibody binding observed by flow cytometry.  
In contrast, silencing of either TbAMPKβ or TbAMPKγ yielded a reduction (but not 
complete ablation) of glycosylated EP-procyclins with a concurrent increase in 
expression of GPEET-procyclin.  GPEET-procyclin expression is characterized by 
expression of full length polypeptides (m/z 6,141) and the presence of a truncated form 
lacking the N-terminus sequence VIVK (marked as "GPEET-4", Fig 4B and 4C) (Acosta-
Serrano, et al., 2000).  Assignments of the procyclins species present in all samples were 
confirmed by negative ion MALDI-TOF-MS analyses of the C-terminus after mild acid 
 115
 
hydrolysis (not shown).  Since the EP-species have the expected masses of polypeptides 
bearing the parental oligomannose N-glycan, the reduction in Con A binding observed in 
TbAMPKβ or TbAMPKγ-deficient cells is not likely due to alteration in N-glycosylation 
but rather is possibly due to masking of the glycan by GPEET-procyclin.   
 
Localization of the TbAMPKβ subunit homolog.  In mammals, the AMPK β-1 
subunit localizes to extranuclear particulate structures that are neither mitochondria nor 
endoplasmic reticulum (Warden, et al., 2001).  The localization and activity of the 
AMPK complex are altered if the AMPK β-1 subunit N-myristolyation site is mutated, 
suggesting that this component of the complex directs the subcellular localization of the 
complex.  To explore the localization of TbAMPKβ, affinity-purified antibodies were 
generated against recombinant TbAMPKβ.  These antibodies recognized a single 
polypeptide (that does not react with pre-immune sera) in western blots of whole 
trypanosomal lysates (Fig. 5A and data not shown). 
 Digitonin fractionation of trypanosomes was used to separate soluble cytoplasmic 
proteins from organellar components.  When this fraction was analyzed by western blot, 
TbAMPKβ was detected exclusively in the particulate fraction (Fig. 5B, P).  As a control, 
the hexokinase activity of each of the fractions was determined and ~90% of the 
hexokinase activity was found associated with the particulate fraction (which should 
include intact glycosomes).  Not all proteins fractionated with the particulate matter, as a 
putative cyclophilin-like protein (Tbcyp22) was found with near-equal distribution in 
both fractions (Fig. 5B).   
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 Immunofluorescence of parasites expressing yellow fluorescent protein (YFP) 
targeted to glycosomes (as a result of fusion with an N-terminal PTS2) was used to 
further assess the cellular localization of TbAMPKβ. These parasites had a TbAMPKβ 
distribution that overlapped with the glycosomal YFP marker but was not exclusively 
glycosomal (Fig. 6A).  For example, signal was also detected in or near the flagellum.  
Similarly, live parasites expressing a fusion of TbAMPKβ with GFP yielded punctate 
fluorescence consistent with glycosomes, as well as faint flagellar signal (Fig. 6B).  YFP 
bearing an N-terminal PTS2 (for glycosome targeting, Fig. 6B, left panel) localizes 
primarily in points in live cells, while expression of GFP without a targeting sequence 
yielded signal throughout the parasite (Fig. 5B, right panel). 
  
DISCUSSION 
The African trypanosome inhabits two very different environments, requiring 
adaptation to conditions found in these different hosts.  In the mammalian bloodstream, 
the parasite is bathed in its primary carbon source, glucose, while in the tsetse fly glucose 
is rapidly depleted during bloodmeal digestion.  In the fly, the parasites persist by 
metabolism of amino acids, taking advantage of the abundance of proline produced by 
the fly to power its flight muscles.   
Both PF and bloodstream parasites monitor glucose abundance to make 
developmental decisions.  During differentiation from BSF to PF, parasites switch 
surface coats from VSG to procyclin in a process that can be triggered in vitro by growth 
in low glucose medium (Milne, et al., 1998).  In the fly, PF parasites respond to changes 
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in glucose concentrations by altering surface molecule expression.  PF parasites very 
early in the differentiation progression express both EP- and GPEET- procyclins, but 
switch to express predominantly GPEET-procyclin shortly after initiation of the infection 
(Acosta-Serrano, et al., 2001, Vassella, et al., 2001, Vassella, et al., 2000).  This switch is 
coincident with the fall of glucose levels during digestion of the bloodmeal.  This 
progression can be recapitulated by growing parasites in very low (0.03 mM) glucose 
conditions or by using RNAi to silence glycolytic enzymes (Morris, et al., 2002).  These 
observations suggest that glucose levels, presumably reflected in the rate of glycolysis, 
are being monitored to regulate GPEET-procyclin expression.    
The molecular mechanisms that govern the expression of the procyclins likely 
differ, as both cis- and trans- factors have been identified (Vassella, et al., 2000, Walrad, 
et al., 2009).  The 3’ UTR of GPEET-procyclin contain a glucose response element 
required for the upregulation of GPEET-procyclin expression in response to low glucose 
medium and during its development in the fly (Vassella, et al., 2004).  EP-procyclin 
expression is likely not regulated by glucose, as culturing parasites in low glucose does 
not ablate EP-procyclin expression (Morris, et al., 2002).  Furthermore, deletion of the 
TbGalE gene, which encodes an epimerase that interconverts UDP-Glc and UDP-Gal in 
glycosomes, leads to a 10-fold increase in the expression of EP- but not GPEET-
procyclin, suggesting that Gal metabolism is also involved in controlling the expression 
and copy numbers of the procyclin molecules (Roper, et al., 2005).   
We have demonstrated here that TbAMPK β and γ play a role in surface molecule 
expression, as silencing of the genes leads to upregulation of GPEET-procyclin 
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expression.  The change in procyclin expression is only detectable when RNAi cells were 
grown in low glucose media, suggesting that the incomplete penetrance of the RNAi of 
the AMPK subunits was not alone sufficient to trigger GPEET expression. 
The physical connection between glucose and surface molecule expression is 
problematic, as the majority of glucose metabolism is compartmentalized in the 
glycosome – how is a signal transmitted from the glycosome to the rest of the cell?  In 
other eukaryotes, AMPK plays a key role in responding to cellular glucose metabolism, 
being activated to trigger changes throughout the cell in response to changes in glycolysis 
(Hardie, 2008).  AMP generated as a result of glucose metabolism could activate a T. 
brucei complex that is homologous to mammalian AMPK (Fig. 7).  Hexokinase and 
phosphofructokinase both consume ATP, which may be regenerated by a glycosomal 
adenylate kinase (ADKD) (Ginger, et al., 2005).  In other systems, this enzyme 
synthesizes ATP from ADP with the concomitant production of AMP and the cells use 
the ATP:AMP ratio as a marker for the status of energy levels (Hardie, 2008).   
Immunolocalization of TbAMPKb indicates a widespread distribution, which 
could reflect the role of the subunit as part of a signaling complex. Although TbAMPKb 
lacks a C-terminal tripeptide peroxisomal targeting sequence (PTS1) (Opperdoes, 1987) 
or a PTS2-type targeting sequence, the subunit partially co-localizes with glycosomes 
(Fig. 5A), where its activity may be influenced by ADKD (Ginger, et al., 2005).  
Additionally, the b subunit localizes to the flagellum, where it is positioned to interact 
with a previously described flagellar AK (Pullen, et al., 2004).  TbAMPKβ subunit 
localization (and function) may be dependent on the protein’s myristoylated state, akin to 
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mammalian AMPK-β1 (Resh, 1999, Warden, et al., 2001). It is also possible that the as 
of yet unidentified a subunit provides cellular targeting information to the complex.  The 
partial localization of TbAMPKβ with glycosomes positions the complex to potentially 
monitor the status of glycolysis in the cell, which has been previously demonstrated to 
play a central role in the modulation of surface molecule regulation.   
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Fig. 1.  Targeting TbAMPKβ and TbAMPKγ by RNAi impacts transcript and protein 
levels. (A) TbAMPK β and γ diagram.  TbAMPKβ contains a putative N-myristoylation 
sequence (MGNTSAE), two conserved Ser residues (corresponding to Ser101 and 
Ser108 from rat AMPKβ1), and a α/γ interaction domain.  TbAMPKγ contains 4 CBS 
domains that have been implicated in AMP binding (Cheung, et al., 2000, Daniel and 
Carling, 2002).  (B) Analysis of RNAi of TbAMPKβ and TbAMPKγ by northern blot.  
Total RNA from parental (-) and tetracycline induced (+) (for 40 h) cells containing the 
construct pZJM(TbAMPKβ) or pZJM(TbAMPKγ) was purified from 5 x 107 parasites 
and electrophoresed on a formaldehyde 1.5% agarose gel.  Ribosomal RNA levels were 
estimated by ethidium bromide staining to ensure equal loading of RNA.  (C.) Western 
blot performed on 5 x 106 or 1 x 106 cell equivalents of PF 29-13 (lanes 1-2) or cells 
induced 4 days to silence TbAMPKβ with pZJMAMPKβ (lanes 3-4) were resolved by 
SDS-PAGE, transferred to nitrocellulose and probed with affinity purified TbAMPKβ 
antibodies.  The bottom panel is a Ponceau S-stained band used to estimate loading. 
 
Fig. 2.  Silencing TbAMPKβ or γ causes a change in surface molecule expression that is 
enhanced by growth in reduced glucose medium. (A.) Living PF 29-13 trypanosomes 
were cultured for two weeks in normal SDM-79 (parental, light grey line) or reduced 
glucose medium (-Glc, dark grey line) and then incubated with 10 mg/ml fluorescein-
conjugated Con A for 15 min at room temperature in cytoM.  Parasites were then 
analyzed by flow cytometry (10,000 cells/assay).  (B.) Cell line PF 29-13 (parental, light 
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grey line), cells induced to silence TbAMPKβ for 7 days (+tet, black line) and cells 
induced to silence TbAMPKβ for 7 days grown in reduced glucose medium for 7 days 
(+tet -Glc, grey line) were analyzed after Con A-FITC staining.  Laser intensity was 
adjusted to yield autofluorescence from unstained cells (purple shade) of ~3 fluorescence 
intensity units.  (C.) Cells in which TbAMPKγ was silenced for 7 days (+tet, black line), 
trypanosomes induced to silence TbAMPKγ for 7 days grown in reduced glucose 
medium (+tet, -Glc, grey line), and cells induced to silence TbAMPKγ for 7 days grown 
in reduced glucose with glucose supplemented (5 mM) (+ tet, -Glc/+Glc, grey line) for 7 
days were analyzed.   
 
 
Fig. 3.  Trypanosomes deficient in either TbAMPKβ or TbAMPKγ express GPEET-
procyclin.  Parasites were grown in normal SDM-79 (light grey line) or reduced glucose 
medium (-Glc, dark grey line), and cells induced to silence TbAMPK subunits for 7 days 
(+tet).  Induced cells were also grown in reduced glucose medium (+tet -Glc), or in media 
with glucose supplemented (5 mM) (+ tet, -Glc/+Glc).  Parasites (5 x 106) were fixed and 
stained with antibodies to EP-procyclin (TBRP1/247) or GPEET-procyclin (monoclonal 
5H3).  Primary antibodies were detected with FITC-conjugated anti-mouse secondary 
antibody and cells (10,000) analyzed by flow cytometry.   
 
Fig. 4.  Mass spectrometry analysis of procyclins.  Butanol extracts of (A) PF 29-13, (B) 
TbAMPKβ, and (C) TbAMPKγ silenced cells grown in low glucose medium were 
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dephosphorylated with aqueous HF and aliquots analyzed by MALDI-TOF-MS in 
positive mode.  Some of the unlabelled ions in B and C correspond to fragments of EP-
procyclins that lack 10 amino acids from the N-terminus (Acosta-Serrano, et al., 2000).  
Asterisks represent a contaminant that has been previously assigned as KMP-11 (Acosta-
Serrano, et al., 1999).  
 
Fig. 5.  TbAMPKβ has an organellar digitonin fractionation.  (A.) Affinity-purified 
antibodies raised against TbAMPKβ recognize a single polypeptide in total T. brucei cell 
lysates.  (B.) TbAMPKβ partitions with the particulate fraction of digitonin permeablized 
cells.  Following fractionation, equal volumes of supernatant and resuspended pellet (1 x 
106 cell equivalents/lane) were resolved by SDS-PAGE, transferred to nitrocellulose, and 
probed with antibodies to either TbAMPKβ (1:100) or Tbcyp22 (1:100).  Primary 
antibodies were detected with HRP-conjugated goat anti-mouse antibodies (1:10,000).  
To explore hexokinase activity, fractions were assayed in a coupled hexokinase reaction, 
with the conversion of NAD to NADH by glyceraldehyde-3-phosphate dehydrogenase 
monitored by spectrophotometer.   
 
Fig. 6.  TbAMPKβ is localized to punctate bodies that partially co-localize with 
glycosomes.  (A.) Immunofluorescence using affinity-pure polyclonal sera raised against 
recombinant TbAMPKβ.  Transgenic PF 29-13 harboring pXS2(PTS2YFP) were fixed, 
permeabilzed , and stained with a mouse anti-GFP monoclonal antibody (left panel) or 
affinity-purified polyclonal anti-TbAMPKβ antibodies (center panel).  Primary antibodies 
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were detected with FITC-conjugated goat anti-mouse or mouse anti-rabbit antibodies, 
respectively.  Scale bar = 5 mm.  (B.) Expression of TbAMPKβ fused to GFP in live cell 
using pLew111(2T7)GFPβ (middle panel). Transformed trypanosomes were induced to 
express the recombinant fusion protein for 4 days by addition of tet (1 mg/ml).  For 
comparison, live cells expressing glycosomally targeted YFP (left panel) or GFP without 
a targeting sequence (right panel) are included.  Cells were washed, resuspended in PBS 
and spotted on slides after mixing with an equal volume of antifade reagent. 
 
Fig. 7.  A schematic representation of the connection of TbAMPK to surface molecule 
expression.  The pathway labeled with a question mark remains to be resolved, as extra-
glycosomal AMP may function to activate TbAMPK.  ADKD, glycosomal adenylate 
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Through genetic manipulation, glycolysis has been shown to be essential to both the 
mammalian bloodstream form (BS) and the insect stage of Trypanosoma brucei. 
Disrupting glycolysis with compounds can kill the parasites. One drug, lonidamine 
(LND, 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid), inhibits T. brucei 
hexokinase 1 (TbHK1), the enzyme in the first step of glycolysis. In vitro studies have 
shown that LND is a potent trypanocidal agent [2]. Here we have screened a panel of 108 
LND analogs for potency as TbHK1 inhibitors and as anti-trypanosomal compounds. Of 
the 108 analogs, 12 analogs were equivalent or better inhibitors of TbHK1 than LND. 
These studies suggest that alteration to the Z3-position on LND can increase TbHK1 
inhibition and toxicity, while changes to the carboxylic acid at the R1 position appear to 
be less inhibitory. 
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Trypanosoma brucei is the causative agent of African sleeping sickness in 
humans and nagana in cattle. The effects of T. brucei on the people of Africa are 
detrimental to the health of individuals as well as the economy of the continent. The 
infected regions of sub-Saharan Africa are also termed “Green Deserts” because of the 
inability to use these regions for agricultural means. An estimated $4.5 billion is lost 
annually in the green desert [1]. Current treatments for T. brucei are quite noxious to the 
host, killing between 3% and 10% of patients [1]. Therefore, alternative drugs that kill T. 
brucei but not the host should be considered. 
Bloodstream form parasites use glycolysis exclusively for energy production. 
Therefore, compounds that inhibit glycolysis may be potential anti-trypanosomal 
compounds. One such inhibitor of glycolysis, specifically targeting hexokinases, is 
lonidamine (LND, 1-(2,4-dichlorobenzyl)-1,H-indazol-3-carboxylic acid). LND is 
currently used as an anti-cancer agent and male contraceptive [3- 4]. It has been approved 
for use in Europe for cancer and is still undergoing trials for use as a male contraceptive. 
Interestingly, LND has been shown to not only inhibit T. brucei hexokinase 1 (TbHK1) 
but to also inhibit cell growth and ultimately kill the bloodstream parasites in culture [5]. 
The reported IC50 and LD50 in bloodstream form parasites for LND are 850 μM and 50 
μM respectively.  
In an attempt to improve the lethality of LND to T. brucei, analogs have been 
generated and their ability to inhibit TbHK1 and kill bloodstream form parasites has been 
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tested. The following paper describes the use of LND analogs on TbHK1 enzyme assays 
and parasite culture growth. 
 
Materials and Methods 
 
Reagents 
Lonidamine (LND, 1-(2,4-dichlorobenzyl)-1,H-indazol-3-carboxylic acid) was 
purchased from Sigma-Aldrich (St. Louis, MO) . The lonidamine analogs were produced 
by the laboratory of Dr. Gunda I. Georg at the University of Minnesota (Twin Cities).  
 
Trypanosome cell culture 
Bloodstream form 90-13 cells (a 427 strain) were grown in HMI-9 media 
containing 10% fetal bovine serum and 10% Serum Plus (Sigma-Aldrich). 
 
rTbHK1 inhibition assays using LND analogs 
Recombinant TbHK1 was produced using previously described techniques [6]. 
Hexokinase assays contained glucose-6-phosphate dehydrogenase (1 unit/assay, EMD 
Biosciences, Inc., San Diego, CA) as a coupling enzyme which reduces NADP+ to 
NADPH when G6-P is oxidized to 6-phosphogluconic acid. The assay was performed in 
final concentrations of 0.1 M TEA, pH7.9 containing 1.0 mM ATP, 33 mM MgCl2, 20 
mM glucose, and 0.75 mM NAD+. Levels of NADPH were measured using a GENios 
spectrophotometer (Phenix Research Products, Hayward, CA) in a 96-well microtiter 
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plate. LND analogs were used at a final concentration of 1 mM for the initial screens. The 
top 12 best inhibiting analogs determined from the initial 1 mM screen were used for IC50 
analysis at concentrations of 1 mM, 500 μM, 100 μM, 50 μM, and 0 μM (DMSO control) 
 
Lethal Dose Assays using LND analogs 
Bloodstream form parasites were grown in 24 well culture plates at a volume of 
1mL HMI-9 culture media. LND analogs were added to the 1 mL cultures at final 
concentrations of 100 μM, 50 μM, 25 μM , 5 μM and 0 μM (DMSO control). Cell 
numbers were determined daily using a Becton-Dickinson FACScan flow cytometer. 
 
Results 
Initial LND analog screen 
In an attempt to minimize the number of IC50 assays preformed, a hexokinase 
assay was used for each analog to determine if the analog is an inhibitor. Many LND 
analogs lost their ability to inhibit rTBHK1 after modification (data not shown). 
However, twelve of the 108 LND analogs tested inhibited rTBHK1 to the same extent or 
better than LND. These 12 analogs share similar modifications at positions R1 and R2 as 
shown in Table 1. 
  
LND analogs reduce IC50 
Previously, the IC50 for LND on rTBHK1 activity was found to be 850 µM [5]. 
Here we find that analogs of LND can improve the IC50 to 250 µM (See Table 1). 
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However, two of the 12 LND analogs, RC-MC-223 and JWS-1-232, were less inhibitory 
even though they were eliminated during the initial screen. RC-MC-223 and JWS-1-232 
exhibited IC50 concentrations of 971.2 µM and 2134.3µM, respectively. 
 
LND analogs reduce LD50 
To determine if modified LND analogs could kill T. brucei we grew bloodstream 
form parasites in the presence of the drug. To date the lowest observed LD50 for an LND 
analog is 3.5 µM when using RC-MC-223 which is an order of magnitude lower than the 
LD50 for LND (50µM, Chambers et al.). Surprisingly, the most potent rTBHK1 enzyme 
inhibitor RC-MC-217 was not the most potent anti-trypanocidal compound with an LD50 
of 80 µM. The LD50 results are summarized in Table 1. 
 
Discussion 
Trypanosoma brucei accounts for a tremendous loss in both human lives and 
economic success for the sub-Saharan region of Africa. Finding safe treatments for T. 
brucei infection should be explored further. The current treatments may lead to 
encephalopathy or death. The LND analog inhibition assay discovered a total of 12 LND 
analogs of interest. These analogs had equivalent or better inhibition of TbHK1 at 1 μM 
final concentration of inhibitor in the assay than the parental LND. A basic trend in the 
side chain alteration was noticed. Many of the effective analogs have an addition of a 
trifluoromethyl group to the Z3 carbon. Also the carboxylic acid was altered by the 
addition of 2 to 3 carbons on the R1 side chain location. These two changes seem to be 
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enhancers of inhibition for LND. Both the IC50 and LD50 suggest that Z3 and R1 positions 
are crucial to the inhibitory nature of LND analogs. Interestingly, many of the non-
inhibitory LND analogs had major changes to these two locations (data not shown). 
Surprisingly, the best inhibitor of TbHK1 enzyme activity, RC-MC-217, with an 
IC50 of 247.2 μM, was not the most potent inhibitor of cell growth, LD50 of 87.6 μM. 
This may be due to a delivery problem within the cell. Potentially, the analog may not 
localize to the glycosome where hexokinase is located. However, another reason for this 
decrease in IC50 but increase in LD50 may be that the analog targets other pathways 
besides just glycolysis in which cell growth could be activated instead of shut down. In 
either case, the best LND analog for killing bloodstream form parasites is RC-MC-223 
with an LD50 of 3.5 μM. The low concentration of 3.5 μM is theoretically achievable 
because in a rat model system, LND was observed to be at a blood serum level of 3-37.3 
μM after 48 hours when 100mg/kg of LND was given orally [7] and in humans plasma 
levels were 14-105 μM after 30 days treatment with 450mg per day given orally [8]. 
Future experiments include testing the most potent LND analogs such as RC-MC-
223 in a mouse model and observing the effects on both the host and the parasite. It will 
be important to determine if the increase in effectiveness of the LND analogs as anti-
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971.2 R1 = 1-propene(3)ol  R2 = trifluoromethyl (Z3 Carbon) RC-MC-223 
410.5 R1 = trans-acrylic acid  R2 = trifluoromethyl (Z3 Carbon)  X = methylJWS-2-224 
274.9 R1 = cis-acrylic acid  R2 = trifluoromethyl (Z3 Carbon) R C-MC-241 
 256.9  R1 = trans-acrylic acid  R2 = trifluoromethoxyl (Z3 Carbon)  X = methyl  JWS-2-232-1 
271.8 R1 = isobutyric acid  R2 = trifluoromethyl (Z3 Carbon) RC-MC-294-1 
 
247.2 R1 = 2-methyl acrylic acid  R2 = trifluoromethyl (Z3 Carbon)RC-MC-217 
IC50 μMB 
Changes from LonidamineAName 
A Changes from Lonidamine: Analogs are the same as LND except where noted in the table 
B Amount (μM) of analog necessary to inhibit TbHK1 activity by 50% 
C Amount (μM) of analog necessary to kill 50% of 90-13 bloodstream form parasites by day 2 
Table 1. LND Analog Changes and IC50/LD50 Data
Lonidamine 
R1 = Carboxylic Acid 
Z1-Z4 = Carbon 
X = Chlorine 
Y = Chlorine
IC50 = 850 μM 














Table 1. LND Analog Changes and IC50/LD50 Data. The LND analogs are described 
along with the corresponding concentration to achieve 50% inhibition and 50% lethal 
dose for each. The locations for changes in the LND molecule are described in the 
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Trypanosoma brucei (T. brucei), the protozoan parasite that causes African sleeping 
sickness in man, annually infects ~500,000 people in sub-Saharan Africa, leading to 
50,000-70,000 deaths per year.  The Special Programme for Research and Training in 
Tropical Diseases (TDR) currently considers the disease a category 1 (emerging or 
uncontrolled) disease (WHO, www.who.int).  Current therapies for African sleeping 
sickness are inefficacious and toxic (Barrett et al., 2003).  The lack of affordable, safe, 
and effective therapies for those infected with the African trypanosome makes the 
identification of new therapeutic leads a priority in our effort to reduce disease in the 
world today.   
 
Here, we have developed methods to identify small molecules via high throughput 
screening (HTS) with differences in toxicity of toward the bloodstream form (BSF) 
parasite, the stage that infects mammals and the procyclic form (PF) parasites, which 
infect the tsetse fly vector. To identify these differences in drug susceptibility, the two 
life cycle stages will be grown in culture and then subjected to a validated HTS assay 
format to identify anti-trypanosomal compounds.  Impact on parasite growth and viability 
will be determined using an alamar blue-based assay that we have developed here is 
simple, reproducible, and well-suited for HTS implementation.  We will then 
systematically confirm the growth inhibitory activity of primary hits using a series of 
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standardized secondary confirmation assays (IC50 determinations for cherry-picked 
compounds, assessment of toxicity toward a mammalian cell line).   
 
BACKGROUND AND SIGNIFICANCE 
African sleeping sickness conjures images of the past - of disease-induced fatal slumber 
striking down men, women, and children while the malady decimates villages of colonial 
Africa.  Unfortunately, people living in many countries of sub-Saharan Africa today 
know that African sleeping sickness is not a disease of history but rather is a much-
neglected disease of the present, particularly in areas that suffer the additional burdens of 
war, famine, and other infectious agents.  A survey conducted by the W.H.O. indicated 
that major outbreaks of African sleeping sickness occurred in 2005 in Angola, the 
Democratic Republic of Congo and Sudan. At the same time, the disease was a major 
public health burden in Central African Republic, Chad, Congo, Côte d’Ivoire, Guinea, 
Malawi, Uganda and United Republic of Tanzania.  While these outbreaks went 
essentially unnoticed in the rest of the world, tens of thousands were infected and untold 
numbers succumbed to the disease.   
 
The African trypanosome, T. brucei is the protozoan parasite that causes African 
sleeping sickness and nagana, a disease of animals.  The parasite lives in the bloodstream 
of the infected mammal as a BSF parasite, consuming host glucose to generate energy 
through glycolysis.  When parasites are taken up by a blood feeding tsetse fly, they 
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differentiate into PF parasites, a form that has adaptations for life in the fly that include 
an active mitochondria that allows for amino acid metabolism.   
 
Current treatments are expensive, dangerous, and difficult to administer.  Most of 
the drugs used in the treatment of African sleeping sickness are antiquated, with only two 
compounds (eflornithine and DB289) being developed since 1950.  Pentamidine, 
melarsoprol, suramin and eflornithine are all difficult and expensive to administer, 
requiring intravenous or intramuscular injections delivered over extended periods of time.  
In addition, most of these drugs are extremely toxic.  For example, melarsoprol, a 
derivative of arsenic, causes brain injuries in 5-10% of patients (50% of which are fatal) 
(Pepin et al., 1991).   
 Due to its lower toxicity, eflornithine (DFMO) is currently the first choice for 
treatment of late stage African sleeping sickness.  However, this drug has drawbacks.  
First, a total of nearly one-half of a kilogram of drug must be delivered over 14 days by 
I.V. injection with treatments every six hours (per the Mayo Clinic recommendations).  
Second, the availability of this drug in the future is in question.  In 1990, Aventis 
discontinued the production of eflornithine for the treatment of African sleeping sickness, 
but did continue its production for use in over-the-counter depilatory creams.  
Negotiations with MSF and the WHO have ensured its production until 2011.  It is 
unknown if the drug will be available after that date.   
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 The most recent therapeutic hope, DB289 (pafuramidine) reached clinical trials 
but has recently been discontinued due to liver and kidney abnormalities in volunteers 
treated with the drug (Immtech Pharmaceutical press release, December 26, 2007). 
 
HTS approaches to identify compounds with anti-kinetoplastid activity – HTS technology 
has been used previously to identify compounds with activity against T. brucei and the 
related kinetoplastid parasite, Leishmania.  Using an ATP-bioluminescence assay, 
Mackey and colleagues screened a library of 2160 drugs that had been developed for 
other uses for anti-T. brucei activity.  This effort yielded 35 compounds with trypanocidal 
activity (Mackey et al., 2006).  More recently, a HTS has been initiated at the UPDDI for 
small molecules that are growth inhibitory to Leishmania major promastigotes (Sharlow 
et al., In Press).  This screen employs Alamar blue to assess cell viability, and when 
implemented against a library of 196,146 compounds resulted in Z-factors 0.9 ± 0.1. 
 
 In addition to “whole cell” HTS, there have been a number of HTS to identify 
probes for important enzymes from the kinetoplastids.  These include screens for 
activators and inhibitors of T. brucei hexokinase 1 (collaboration between the PI and 
UPDDI), screens for activators and inhibitors of L. mexicana pyruvate kinase (Malcom 
Walkinshaw, Hugh Morgan and Linda Gilmore, University of Edinburgh, Edinburgh, UK 
and the National Institutes of Health Chemical Genomics Center (NCGC)), a screen for 
inhibitors of trypanothione reductase (Martyn et al., 2006), and a screen for inhibitors of 
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cruzain from T. cruzi (Brian Shoichet, University of California, San Francisco and 
NCGC). 
 
Significance: This work is part of our overall research effort focusing on the elucidation 
of the mechanisms involved with growth and viability of BSF and PF T. brucei life cycle 
forms.  The primary goal of this effort is to discovery novel, potent and specific inhibitors 
of the growth/viability of T. brucei.  High throughput methodologies, used in conjunction 
with available open source datamining tools (e.g. PubChem) as well as genetic tools such 
as RNA interference-based libraries, can rapidly identify potential molecular targets and 
signaling pathways critical for T. brucei growth and viability.  Moreover, these efforts 
can also rapidly identify novel chemotypes that may serve as the basis for novel drug 
discovery.  This is particularly relevant since drugs for the treatment of African sleeping 
sickness are ineffective and toxic; and, there is a desperate need for new safe and 
effective drugs (Barrett et al., 2003).  While HTS approaches to identify anti-
trypanosomal compounds have been used by others [(Mackey et al., 2006) for example] 
the need for additional chemotypes to provide the basis for diversification of the arsenal 
of anti-parasitic drugs is clear, as parasitic protozoa have a well-documented propensity 
for the development of resistance to therapeutics.  Resistance to suramin [both laboratory 
generated resistance (Scott et al., 1996) and in veterinary applications against a related 
parasite (El Rayah et al., 1999)] and resistance to eflornithine (Bacchi et al., 1993) raise 
concerns that these compounds will eventually be less useful as anti-trypanosomal drugs.  
 Here, we have developed two closely related alamar blue-based HTS assays for 
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the identification of trypanocidal compounds through collaboration with the UPDDI that 
could lead to the development of much-needed new therapies.  Further, the compounds 
identified here will become chemical probes to allow for comparative analysis of the 
biology of different lifecycle stages of the African trypanosome (i.e. BSF versus PF life 
cycle forms) as well as with Leishmania, a related genus. 
 
Rationale for screening for anti-trypanosomal small molecules.  
A.  Probe for differences in the biology of BSF and PF parasites– Some compounds will 
likely be more toxic (or exclusively toxic) to BSF parasites.  For example, probes that 
inhibit glycolysis may be more toxic to the BSF parasite than PF parasites, as BSF rely 
exclusively on glycolysis for energy production, while PF also metabolizes amino acids 
and can grow under glucose depleted conditions.   Once an inhibitor has been identified 
we can use gene knockouts, transgene expression and RNAi to characterize the molecular 
targets of these inhibitors.   
 
B.  Identify desperately needed anti-trypanosomal lead compounds – Therapies currently 
used to treat infections are unsatisfactory due primarily to toxicity (Barrett et al., 2003), 
so the development of new anti-parasitic compounds is essential.  According to Médecins 
Sans Frontières, the group responsible for the majority of primary care for afflicted 
individuals, “… the greatest obstacle to fighting the disease is the lack of new, better 
diagnostic tools and medicines,” 




C.  Reveal differences between T. brucei and Leishmania – Recently a HTS has been 
performed at the UPDDI to identify probes that are toxic to Leishmania major 
promastigotes and intracellular amastigotes.  While T. brucei and Leishmania are both in 
the order Kinetoplastida, their distinct biology (BSF T. brucei is exclusively extracellular, 
while Leishmania can infect host cells, for example) suggests that probes to unique 
biology will be identified. 
 
3.  RESEARCH DESIGN AND METHODS 
T. brucei viability is a promising focus for HTS for the following reasons: 
 
A.  Current therapies for African trypanosomiasis are not suitable. 
B.  Many molecular tools have been developed in the T. brucei system for understanding 
gene function – these will work collaboratively with the probes identified here. 
C.  A simple and reproducible assay has successfully been modified for use in a 96-well 
format. 
 
3.A.  Assay Development 
  
The primary assay used is an adaptation of an alamar blue-based cell viability assay 
(using Cell-Titer Blue) to a 96-well format (Fig. 1).  We have experience with this assay 
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format, which measures the reduction of resazurin to resorufin by cellular processes and 
is well-suited for HTS development and implementation (Fig. 2).     
 
In vitro growth conditions for BSF and PF parasites – Trypanosoma brucei brucei PF 
parasites (strain 29-13) and BSF parasites (strain 90-13) were grown as described (Wirtz 
et al., 1999; Morris et al., 2002; Morris et al., 2001).  This subspecies of parasite infects 
cattle and rats and is routinely used as a model African trypanosome, in part because 
tools for molecular genetics (including RNAi vectors, over-expression cassettes, and gene 
knockout approaches) have been developed using this line (Wirtz et al., 1994; Biebinger 
et al., 1997; Wirtz et al., 1999).  
 
Alamar blue-based assessment of parasite population health.   
 
BSF parasites.  To establish parameters for the preliminary assay described below, 
parasites were seeded at 5 x 103, 5 x104, 5 x 105 cells/well into 96-well clear bottomed 
polystyrene plates in 100 ml of growth medium (HMI-9, see below).  Cells were then 
grown in 5% CO2 at 37C and then alamar blue (commercially available as CellTiter Blue 
reagent from Promega, Madison, Wisconsin) was added to a final concentration of 16% 
(v/v).  Plates were then incubated under standard culture conditions for 1,2, or 4 hours 
and fluorescence of samples characterized by excitation at 546nm with scoring of 
fluorescence emission at 585nm (Fig. 2, top).  After an initial lag in growth (a phenomena 
seen when BSF parasites are transferred from growth in flasks to microtiter plates), BSF 
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growth is linear.  As BSF trypanosomes typically double every 8-12 hours, the 
fluorescence (within standard deviation) is a reasonable reflection of the doubling rate of 
the trypanosomes.  Please note that the population continues to grow until the population 
reaches ~1 x 107/ml, at which point the parasites die.  
 
PF parasites.  Parasites seeded at 5 x 103, 5 x104, 5 x 105 cells/well into 96-well clear 
bottomed polystyrene plates were cultured in 100 ml of growth medium (SDM-79, see 
below).  While PF doubling time is density dependent, PF cultures between 5x105 – 1 x 
107/ml typically double every 16-18 hours.  PF parasites are less sensitive than BSF to 
overgrowth, reaching a stationary phase (at >1.5 x 107 cells/ml) that can persist for 
several days before the culture begins to die (Fig. 2, bottom). 
 
Thus, we have determined that both T. brucei life cycle forms can effectively metabolize 
the alamar blue reagent, setting the stage for development of the HTS assay format. 
 
 
Initial assessment for suitability of assay format for HTS development 
 
Bloodstream Form Trypanosomes.  Briefly, 5 x 103 parasites were seeded into 96-well 
clear-bottomed polystyrene plates in growth medium (see below for specific differences 
for BSF and PF parasites).  For background signal, cells were grown in the presence of 
the trypanotoxic compound quercetin dihydrate (100 µM) (Mamani-Matsuda et al., 
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2004).  Cells were then grown for 3 days in 5% CO2 at 37C and then CellTiter Blue was 
added to a final concentration of 16% (v/v).  Plates were then incubated for 3 hours under 
standard culture conditions.  Fluorescence of samples was then characterized by 
excitation at 546nm with scoring fluorescence emission at 585nm.  Preliminary results 
indicate that DMSO is well tolerated by BSF parasites and has minimal impact on the 
assay described here, with 1% DMSO (f.c.) causing a 16% reduction in cell number at the 
end of the three day assay.   
 
In the 96 well format, 96 wells of parasites grown in the presence of carrier (1% DMSO) 
generated a mean fluorescence intensity of 27052 (+/- 3431) compared to quercetin killed 
parasites, which yielded fluorescence of 3697 (+/- 163).  These values generated a Z 
factor value of 0.62 (Fig. 3).  The maximum background well value was 5.8-fold lower 
than the well with the lowest value that contained cells (3676 compared to 21184).  
 
Dose-dependence of the alamar blue-based assay.  To assess the dose dependence of the 
assay using an anti-parasitic compound, BSF parasites were incubated with varying 
amounts of an experimental trypanocidal compound (PubChem SID 371557) and cell 
viability determined using CellTitre Blue (Promega) as described above.  Increasing 
levels of the compound was toxic to T. brucei (Fig. 4), and the percentages of remaining 
viable cells were in good agreement with the values determined by microscope and 
hemacytometer.  While we cannot differentiate between cytostatic and cytocidal 
compounds using the CellTitre Blue-based assay, both types of probes would be useful 
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leads, as trypanosomes must divide to establish successful infections by avoiding the host 
immune response as a result of antigenic variation (the replacement of one surface-coat 
bearing population with another). 
 
Procyclic Form Trypanosomes.  Parasites (5 x 104/well) were grown in 96-well clear 
bottomed polystyrene plates (with background cells treated with quercetin, as described 
above) in growth medium for 2 days in 5% CO2 at 25C and then CellTiter Blue was 
added to a final concentration of 16%.  Plates were then incubated for 1 hour under 
standard culture conditions.  Fluorescence of samples was then characterized as above.  
As with the BSF, DMSO has minimal impact on the PF assays when included in assays at 
1% (f.c.) for the 2 day assay.   
 
In the 96 well format, vehicle treated parasites yielded a mean fluorescence 
intensity of 14768 (+/- 1185) compared to the quercetin-killed cells, which had a mean 
fluorescence of 2804 (+/- 62.3).  These values yielded a Z factor value of 0.69 for the 
entire plate (Fig. 3).  The maximum background well value was 4.1-fold lower than the 
well with the lowest value that contained cells (2983 compared to 12363).   
 
For both T. brucei life cycle forms, these results suggest that the assay format will 
be amenable to HTS assay development and implementation procedures.  Thus, studies 
will focus on: (a) generating a T. brucei parasite bank; (b) confirming growth 
characteristics of the life cycle forms to ensure harvesting each T. brucei lifecycle form in 
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exponential growth phase; (c) determining optimal seeding densities, culturing conditions 
and timing of the assay; (d) capturing data within the linearity range of signal readout; 
and (e) confirming the developed assay parameters with known T. brucei growth 
inhibitors.  Moreover, in the 384-well HT screens for both cell types, assay plates will 
include maximum (DMSO vehicle), minimum (quercetin inhibited signal) and IC50 
controls (Sharlow et al., 2008).   
 
3.B. Configuration of Assays for HTS 
To configure the assay format to an HTS amenable format additional studies will be 
conducted to (a) define the DMSO tolerance of each life cycle form; (b) identify the 
maximum and minimum assay controls from which the HTS Z-factor statistic will be 
derived; (c) conduct a three-day variability assessment to determine predicted plate-to-
plate and day-to-day variability as well as coefficient of variance and signal to 
background; and (d) validate the optimized HTS assay conditions using the LOPAC set 
to determine hit criteria and screening concentration as well as identify initial differences 
in chemosensitivities between the BSF and PF life cycle forms (Sharlow et al., 2007).     
 
Evaluate Significance of active compounds – Primary hits identified from the validated 
HTS assays will progress through a series of secondary confirmation assays.  To confirm 
the activity of the primary hits (and thus eliminate false positives), 10 point IC50 
determinations will be conducted (in duplicate) with the hit compounds using the 
optimized HTS assay parameters. To be considered as a T. brucei growth inhibitor, 
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compounds must confirm in each 10 point IC50 determination run.  Based on previous 
experience with the L. major promastigote assay where we identified nanomolar as well 
as picomolar inhibitors of L. major promastigote growth, it may be necessary to run 20 
point concentration determinations.  Thus the starting concentration of the concentration 
response assessment will be determined by the final screening concentration (e.g. 1 or 5 
µM) of the LOPAC library.  Additionally, confirmed actives from the screened library 
will be purchased (or otherwise obtained) and retested to confirm growth inhibitory 
activity.  This will control for lot-to-lot compound variability as well as for inhibitory 
activity that may be the result of compound degradation within the compound library.  It 
is also possible that some of the natural compounds that will be screened will fluoresce 
around 585nm, thus other cell viability assays, including those that measure ATP 
production using luciferase, would be considered if the interfering signal routinely causes 
problems as well as to confirm the inhibitory activity of the compound in another assay 
format.  
 
Plans to develop counter-screens (selectivity and potential toxicity)  
 
Counter-screening against mammalian cells.  Confirmed trypanosome growth inhibitors 
will be screened against mammalian cells to initially assess selectivity as well as potential 
toxicity to the host, with IC50 values determined using the CellTiter Blue reagent.  These 
counter-screening assays are available at the UPDDI and include HTS validated cancer 




Additional analysis. During a T. brucei infection, parasites evade the host immune system 
by a process known as antigenic variation.  In this process, the majority of the infectious 
population harbors a given surface coat antigen.  After 10-14 days, it is eliminated by the 
host immune system, only to be replaced by a new population that expresses an 
antigenically distinct coat.  The new population grows until it too is eliminated and 
replaced.  This suggests that compounds that are cytostatic would prevent parasite growth 
(and therefore population replacement) and therefore antigenic variation.  Growth curve 
analysis (and microscopic examination) can be employed to determine whether 
confirmed actives are growth inhibitory or cytotoxic (Chambers et al., 2008).   
 
Additionally, confirmed T. brucei growth inhibitors will be screened using a validated 
Leishmania major promastigote HTS assay (Sharlow et al., In Press), in order to explore 
the species selectivity of small molecule probes.    
 
This proposal seeks to identify probes that are toxic to BSF and PF parasite life stages. 
These stages occupy distinct niches, and as a result, harbor a remarkable number of 
different biochemical pathways.  Stage-specific anti-parasitic compounds would therefore 
provide insight into biochemical differences between the PF and BSF parasites.  For 
example, PF parasites decorate the GPI anchors of their major surface glycoprotein with a 
variety of fatty acids, while BSF parasites include myristate exclusively in their mature 
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GPIs.  A compound that specifically targets the myristate incorporation pathway may 
therefore be toxic to only the BSF parasite.   
 
Recommendations for test concentrations and concentration cutoff – The screening of the 
LOPAC library will be performed at two concentrations, 1 and 10 µM and the hit rates 
(based on 50% inhibition of signal readout) will be determined for each of the tested 
concentrations.  Thus, the screening concentration of subsequent libraries will be 
determined by the hit rate as predicted by the LOPAC library.  Ideally the hit rate for the 
LOPAC set would be 1% or lower to ensure that there will be a reasonable number (not 
an excessive quantity) of primary hits that would be cherry-picked for secondary 
screening procedures.  This is especially important when screening larger compound 
libraries.  Structure activity relationships can be developed for promising lead compounds 
(those with IC50s in the nM range).   
 
Reagent sources and costs - The reagents and consumables required for the primary HTS 
assay are commercially available except for the two life stages of the trypanosome and 
potential inhibitors. 
 
a.  Bloodstream Form Trypanosomes –  BSF strain 90-13 express the T7 RNA 
polymerase and the tetracycline repressor (Wirtz et al., 1999).  The T7 RNA polymerase 
and the tetracycline repressor are maintained by culturing the parasites in the presence of 
2.5 µg/ml G418 and 5 µg/ml hygromycin. (These are dispensable here, so drug selection 
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is not required for the HTS.  This strain and the corresponding PF strain will be essential 
to future studies using molecular genetics, hence our interest in using it during the HT 
screen.) The parasites are grown in HMI-9 supplemented with 10% fetal bovine serum 
and 10% Serum Plus (JRH Biosciences, Lenexa, KS) (HMI-9/FBS10) (Hirumi et al., 
1989), with cell densities maintained between 1 x 104 - 1 x 106 cell/ml.  Maintaining the 
cultures between these densities is essential, as overgrowth is lethal to the BSF parasites.  
Prior to adding parasites, the medium is warmed to 37C and equilibrated to 5% CO2 for 1 
h in the growth incubator.  (Please note that clonal populations are routinely generated by 
limiting dilution into 96 well plates, so parasites are amenable to growth in plates.) 
 
HMI-9 for BSF growth (Hirumi et al., 1989) - For 1 liter, mix the following dry 
ingredients: Hypoxanthine (136 mg), bathocuproine sulfonate (28 mg), cysteine (182 
mg), pyruvic acid (110 mg), thymidine (39 mg) 
 
Add the dry ingredients to the following liquids: 2-mercaptoethanol (14 ml), Iscove’s 
Modified Dulbeccos’s Medium with L-glutamine and HEPES (730 ml), 
penicillin/streptomycin solution 100X (10 ml). 
 
Adjust volume to 800 ml, filter sterilize and add heat-inactivated fetal bovine serum (100 
ml) and Serum Plus Medium Supplement (100 ml) (from JRH Biosciences).  Store at 4C 




Cost (per liter): $27.75 + 10% serum ($52.60) + 10% Serum Plus ($50.00) = $130.35/L 
 
b.  Procyclic Form Trypanosomes –  PF strain 29-13 (Wirtz et al., 1999), which harbors 
integrated genes for T7 RNA polymerase and the tetracycline repressor, are grown in 
SDM-79 supplemented with 10% FBS (SDM-79/FBS10) (see below).  
 
SDM-79 for PF trypanosome growth  [slightly modified from (Brun et al., 1979)] - For 1 
liter, mix the following dry ingredients: Grace’s Insect Cell Culture Media with L-
glutamine and without sodium bicarbonate (2.0 g), glucose (1.0 g), HEPES (8.0 g), 
MOPS (5.0 g), NaHCO3 (2.0 g), pyruvic acid (100 mg), L-alanine (200 mg), L-arginine 
(100 mg), L-glutamine (300 mg), L-methionine (70 mg), L-phenylalanine (80 mg), L-
proline (600 mg), L-serine (60 mg), L-taurine (160 mg), L-threonine (350 mg), L-
tyrosine (100 mg), adenosine (10 mg), guanosine (10 mg), D-glucosamine-HCl (50 mg), 
folic acid (4 mg), p-aminobenzoic acid (2 mg), biotin (0.2 mg). 
 
Dissolve the dry solids (20.2 g) in the following: Minimum Essential Medium (MEM) 
with L-glutamine (600 ml), MEM amino acid solution 50X without L-glutamine (8 ml), 
MEM non-essential amino acids 100X (6 ml), bovine hemin (2 mg/ml in 50 mM NaOH) 
(3.75 ml), Basal Medium Eagle vitamin solution 100X (10 ml), penicillin/streptomycin 




Adjust the pH to 7.3 with 10 N NaOH, and increase the volume to 850 ml with H20.  
Filter sterilize with a 0.22 mm filter.  Add heat-inactivated (56C, 30 min) fetal bovine 
serum (150 ml) to the filtered solution – do not filter the serum.  Store at 4C for up to 6 
months. 
 
Cost (per liter): $27.75 + 15% serum ($78.90)  = $106.65/L 
 
c.  Other Solutions for Parasite Husbandry -  
 
Freezing medium - 50% glycerol in cytomix, filter-sterilized.  Once parasite lines have 
been established, a portion of the culture should be stored for future use. To freeze 
trypanosomes, freezing medium (0.2 ml of 50% glycerol in cytomix that has been filter-
sterilized) is added to 0.8 ml of culture containing 1-5 x 106 cells/ml in a liquid nitrogen 
compatible cryotube.  The cells are mixed thoroughly by inversion, and then frozen at –
80C overnight in a modified trypanosome freezing carton.  This carton is made of two 
Styrofoam racks (in which 15 ml conical centrifuge tubes are shipped) taped together; 
samples placed in the carton freeze more slowly than exposed tubes.  The cryotube is 
then transferred the next day to liquid nitrogen.  To thaw PF trypanosomes, frozen 
cryotubes are warmed to room temperature, and the contents of a single tube are 
transferred to 9 ml SDM-79/FBS15/G/H and grown at 27C in 5% CO2.  To thaw frozen 
BSF trypanosomes, cryotubes are warmed to room temperature, and the contents are 




d.  Other reagents 
LOPAC library daughter set -  $1000 
Control reagents (known inhibitors) $  250 
 
Pilot screening of a library of pharmaceutically active compounds (LOPAC) - Assay 
development procedures, including tests for required optimization of assay parameters, 
HTS assay control identification, parasite banking, and three day variability assessment 
will require ~3-4 months, with an additional month for completion of validation and the 
LOPAC screen (1280 compounds).   
 
Conclusions and outlooks:  
The lack of affordable, safe, and effective therapies for those infected with the African 
trypanosome makes the identification of new therapeutic targets a priority in our effort to 
reduce disease in the world today (Barrett et al., 2003).  We will identify new lead 
compounds for anti-trypanosomal therapies and we may, through the genetic and 
comparative approaches proposed here, identify compounds that target a particular 
parasite pathway, allowing further elucidation of the function of that pathway in the 
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Figure 1.  Cell-Titer Blue reactions scheme. 
 
Figure 2. Growth curves, as monitored by CellTiter Blue fluorescence.  BSF (seeded at 5 
x 103/well) or PF (seeded at 5 x 104/well) were grown for the indicated days and then 
incubated with CellTiter Blue for the indicated number of hours and fluorescence 
monitored as described.  Please note that “over flow” signal (saturation) was at 5 x 104 
RFU. 
 
Figure 3. Z factor determination for BSF (upper) and PF (lower) parasites (see text for 
details) grown in carrier (1% DMSO, open symbols).  The background signal (filled 
symbols) was determined using cells were grown in the presence of the trypanotoxic 
compound quercetin dihydrate (100 µM).  
 
Figure 4. Monitoring dose-dependent response to an anti-parasitic compound using 
CellTiter Blue.  BSF parasites (5 x 103) were grown for in the presence of an 
experimental trypanocidal compound (PubChem SID 371557) for 3 days and then 
CellTiter Blue was added to the cultures and incubated an additional 3 hours prior to 
assessing fluorescence emission. 
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